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Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours characterized
by early metastases and poor prognosis. Discovering novel biomarkers and therapeutic
targets is necessary to improve TNBC patient outcomes as resistance to chemotherapy, the
main therapeutic approach for TNBC, is common. In my study, RHAMM promoted
proliferation of TNBC MDA-MB-231 tumour cells. RHAMM expression increased
sensitivity to doxorubicin (p=0.0002) and strongly increased sensitivity to the FDAapproved MEK1/2 inhibitor trametinib (p≤0.0001). Doxorubicin and trametinib selectively
killed RHAMM+/+ MDA-MB-231 tumour cells grown as co-cultures with RHAMM-/- MDAMB-231 tumour cells. RHAMM-loss or trametinib decreased phosphorylated ERK1/2
protein levels and promoted apoptosis through cell surface RHAMM/HA interactions. The
combination of paclitaxel, a chemotherapeutic, and trametinib synergistically promoted
apoptosis of the RHAMM+/+ MDA-MB-231 tumour cells. Therefore, RHAMM is a
candidate novel biomarker in TNBC, and its expression can be exploited for targeted
therapy, which has potential clinical utility for the management of TNBC.

Keywords
Triple-negative breast cancer, targeted therapy, RHAMM, hyaluronan, tumour
microenvironment, biomarker, drug response, MEK therapy
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Summary for Lay Audience
Triple-negative breast cancer (TNBC) is a type of breast cancer characterized by invasive
tumour growth and poor patient survival outcomes. Development of resistance to current
treatments, such as doxorubicin, is common. Therefore, identifying and developing
effective therapies is required to improve patient outcomes. A protein called RHAMM has
been reported to be highly expressed in breast cancer and my project was therefore focused
on assessing if RHAMM expression in TNBC can help identify tumour cells that are more
likely to die when exposed to different treatments, such as chemotherapy. In my study, the
loss of RHAMM reduced TNBC cell proliferation, in part through the regulation of a
protein called ERK1/2, which is highly expressed in TNBC. RHAMM expression increased
the sensitivity of TNBC cells to the chemotherapeutic drug doxorubicin and trametinib, a
drug that specifically targets MEK1/2, which is a highly active protein that promotes cancer
progression. Doxorubicin and trametinib selectively killed RHAMM-expressing TNBC
tumour cells that were grown with TNBC tumour cells that did not express RHAMM.
RHAMM-loss or treatment with trametinib decreased the expression of activated ERK1/2
in the TNBC tumour cells and killed the tumour cells through the cell surface interaction
of RHAMM and its binding partner HA. Furthermore, the combination of trametinib and a
chemotherapy agent paclitaxel killed more RHAMM-expressing TNBC tumour cells than
treatment with either drug alone. My results suggest that RHAMM expression in TNBC
can be used as an indicator of sensitivity to treatment and that its expression and signalling
can be used for targeted therapy, which has potential clinical significance for the
management of TNBC.
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Chapter 1
1

Introduction
1.1

Breast cancer

Breast cancer is one of the most common cancers among women. It is projected to account
for approximately 1 in 4 new cancer cases in Canada in 20221, and be the fourth most
common cancer-related death overall in Canada in 20222. Breast cancer is a heterogeneous
disease, broken down into multiple subtypes based on molecular, histological, and clinical
characteristics3. Histologically, breast cancer can be categorized into in situ carcinomas,
which refer to cancer cells that do not migrate from their primary location, or invasive
carcinomas3,4 (Figure 1). There are two types of in situ carcinomas: ductal and lobular.
Ductal carcinoma in situ forms in milk ducks, whereas lobular carcinoma in situ forms in
breast lobules3,4. Invasive carcinomas are a heterogeneous group of tumours that result from
the migration of ductal and lobular cancer cells into the breast tissue and eventually into
other tissues3. Increased importance has been placed on the molecular classification of
tumours because survival outcomes and response to therapy can be predicted based on a
tumours genomic and transcriptomic profile. Breast cancer tumours are currently divided
into six main molecular subtypes based on estrogen receptor (ER), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2) and Ki67 gene expression: normal
breast-like, HER2-enriched, luminal A, luminal B, basal-like, and claudin-low3,5–7. Out of
all the subtypes, patients with the basal-like subtype experience the shortest overall survival
rates5,6.
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Figure 1. Histological and molecular classification of breast cancer. Histological
classifications are based on morphological features of the tumour and its growth patterns.
Molecular classifications are based on gene expression analysis of estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67
expression. DCIS: Ductal carcinoma in situ; LCIS: Lobular carcinoma in situ. This figure
was adapted from Malhotra et al., 20103.
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1.2

Triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours within the
basal-like subtype that comprise 10 – 15 % of all breast cancers7–10. TNBC is defined by
the absence of ER, PR, and HER2 expression7,11, and is categorized into six
subclassifications: basal-like 1 (BS1), basal-like 2 (BS2), immunomodulatory (IM),
luminal androgen receptor (LAR), mesenchymal (M), and mesenchymal stem-like (MSL),
based on gene expression profiling12,13 (Figure 2). TNBC is typically highly invasive with
poor prognosis7–9. Relative to patients with other breast cancer subtypes, TNBC patients
are more likely to experience distant tumour metastases in the brain and lung tissue within
the first three years after diagnosis7,8,10,14,15. Additionally, TNBC patients have a worse
overall survival rate at every tumour stage16 and experience higher mortality within the first
five years of diagnosis9,17 compared to patients with other breast cancer subtypes.
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Figure 2. Histological and molecular classification of triple-negative breast cancer.
Triple-negative breast cancer is termed “triple-negative” because these tumours lack
expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2). Molecular classifications are based on gene expression
profiling of TNBC tumours.
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1.3

Systemic chemotherapy treatment options for TNBC

The use of biomarkers is an important strategy to determine patient response to therapy.
Biomarkers can help clinicians both identify the aggressive status of a tumour and inform
on how tumours will respond to chemotherapy and targeted treatments9,18,19. However,
chemotherapy without biomarker guides remains the main systemic treatment for TNBC
largely because this subtype does not express ER, PR and HER2, which are the most
commonly used biomarkers for providing direction for treatment (e.g. HER2-positive
breast cancer patients respond well to treatment with the HER2 inhibitor trastuzumab)7,9.
Doxorubicin (Adriamycin) + cyclophosphamide (AC) chemotherapy or AC followed by a
taxane (paclitaxel or docetaxel) chemotherapy is one of the main treatments administered
to all ER-, PR- and HER2-positive breast cancer patients before their primary therapy of
surgery or targeted therapy20. In contrast, there are no standard chemotherapy procedures
for TNBC. The National Comprehensive Cancer Network recommends six different
adjuvant chemotherapy regimens, which occur after the primary surgery, for TNBC based
on combinations of anthracycline, cisplatin, taxane, cyclophosphamide, and fluorouracil:
adriamycin + cyclophosphamide (AC), docetaxel + cyclophosphamide (TC), docetaxel +
adriamycin + cyclophosphamide (TAC), cyclophosphamide + adriamycin + fluorouracil
(CAF), cyclophosphamide + methotrexate + fluorouracil (CMF), or cyclophosphamide +
epirubicin + fluorouracil + a taxane (CEFT). Anthracycline or anthracycline and taxane
chemotherapies are an effective option for some TNBC patients who have a complete
pathological response, which refers to the disappearance of all the cancer cells upon
treatment7,9,12,20. Nevertheless, even following high sensitivity to initial chemotherapy
treatments, the majority of TNBC patients experience residual disease with consequent
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disease recurrence and poor overall survival outcomes14,17,20. Therefore, current research is
focused on identifying novel molecular targets based on the subclassifications of TNBC to
improve treatment outcomes.

1.4

Targeted therapy options in TNBC

Predictive markers to identify TNBC patients who will experience a pathologically
complete response after chemotherapy do not exist9. However, identifying molecular
characteristics of a tumour has proven beneficial in improving treatment response to TNBC.
For example, a retrospective analysis of TNBC patients who underwent anthracycline and
paclitaxel chemotherapy found that amongst the BL1, BL2, MSL and LAR TNBC
subtypes, patients with the BL1 subtype had the highest complete response of 52%,
followed by the MSL, LAR and BL2 subtypes, with responses of 23, 10 and 0%,
respectively21. Multiple preclinical and clinical studies have explored the effect of targeted
treatments based on TNBC subtypes. For example, the BL1 TNBC subtype is characterized
by DNA repair and cell cycle regulation abnormalities, such as germline mutations in the
breast cancer 2 (BRCA2) gene13,22. DNA repair is facilitated by multiple repair pathways,
such as mismatch repair, non-homologous end joining and homologous recombination23,24.
BRCA1 and BRCA2 are a set of genes within the DNA repair pathway important for
homologous recombination after double-stranded breaks. The prevalence of germline
BRCA1/2 mutations is highest in TNBC patients compared to other breast cancer
subtypes7,12,25. Therefore, platinum salts, genotoxic drugs, or inhibitors against poly
adenosine diphosphate ribose polymerase (PARP), which is important for base-excision
repair, are often used against these tumours because they induce massive DNA damage and
consequently promote tumour cell apoptosis21,26. Two phase III clinical trials, OlympiAD
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and EMBRACA, were conducted to assess the overall response rates of TNBC patients
with germline BRCA1/2 mutations treated with PARP inhibitors with the idea that deficits
in DNA repair caused by non-functional BRCA genes make cells sensitive to further
inhibition of DNA repair proteins. In the OlympiAD clinical trial, olaparib, a PARP
inhibitor, increased the median progression-free survival from 4.2 to 7 months and patients
had an overall response rate of 59.9% compared to a chemotherapy response rate of
28.8%27. In the EMBRACA clinical trial, the PARP inhibitor talazoparib increased the
median progression-free survival from 5.6 to 8.6 months and patients had an overall
response rate of 62.6% compared to a chemotherapy response rate of 27.2%28. However,
significant improvements in overall survival relative to chemotherapy were not
observed27,28. Since the clinical benefits of administering PARP inhibitors as a single-agent
neoadjuvant treatment are limited26, additional clinical trials using PARP inhibitors with
DNA-damaging chemotherapy or in a neoadjuvant setting are underway and showing
promise29–31.
Androgen receptor (AR) inhibitors are commonly recommended for the treatment of LAR
tumours since these tumours are driven by overexpression of AR and subsequent AR
signalling13. Clinical studies exploring the effect of the AR inhibitors bicalutamide and
enzalutamide have shown low clinical benefit rates (<30%) in AR-positive TNBC
patients32,33. However, because LAR tumours also display high rates of phosphoinositide
3-kinase (PI3K) mutations13,34, recent preclinical and clinical trials combining AR
inhibitors with PI3K inhibitors have shown improved clinical benefit22,35.
Growth factor receptor inhibitors, such as those inhibiting the epidermal growth factor
receptor (EGFR) or the nerve growth factor receptor, are effective against BL2 tumours
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because the signalling pathways associated with these growth factors are often abnormally
activated36–38. A randomized phase II clinical trial in TNBC patients explored the effect of
cetuximab, a monoclonal antibody targeting EGFR, or the combination of cetuximab and
carboplatin. Response rates were only 6 and 17%, respectively39. In another randomized
phase II clinical trial, the addition of cetuximab to metastatic TNBC patients receiving
cisplatin increased the response rate from 10% to 20% and slightly increased progressionfree survival from 1.5 to 3.7 months. However, the primary endpoint (overall response rate)
of the study was not met40. Thus, despite positive experimental results, EGFR inhibitors
have shown limited benefit in a clinical setting of TNBC cancer8,9.
The IM subtype of TNBC is highly enriched with genes associated with the immune
system, such as T-cell receptor genes and interferon regulatory factors13. Immune
checkpoint inhibitors against immune markers such as programmed cell death protein 1
(PD1) and programmed death-ligand 1 (PDL1), a receptor-ligand system that mediates
suppression of anti-tumour immune responses, are often administered for these tumours13.
Clinical trials targeting PD1/PDL1 have overall response rates of less than 20%41,42.
However, patients who respond well to treatment experience better overall survival rates42.
More research exploring the effect of schedule dependency and combination therapies with
chemotherapy agents is underway43.
The M subtype of TNBC is defined by the activation of pathways important for migration
and differentiation13, whereas the MSL subtype is defined by high expression of stemrelated genes13. Drugs that target migration, such as those against mammalian target of
rapamycin (mTOR), are hypothesized to be effective against M tumours44, while Src and
PI3K inhibitors are hypothesized to be effective against MSL tumours45. In phase I study,
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the response rate of TNBC patients with the M subtype treated with the mTOR inhibitors
temsirolimus and everolimus was only 21%46. Moreover, a phase I study was conducted to
explore the effect of inhibiting NOTCH signalling using a γ-secretase inhibitor, since
NOTCH signalling is important for stem cell development and differentiation47,48, and
because the NOTCH pathway is upregulated in M and MSL TNBC subtypes49. However,
most of the patients had to discontinue using the inhibitor due to disease progression and
the overall response rate was low49.
While these studies demonstrate the benefits of applying targeted therapies to improve
treatment response in TNBC, they also highlight the need for additional markers to identify
treatment-susceptible tumours.

1.5

The role of the RAS/RAF/MEK/ERK cascade in TNBC

Mitogen-activated protein kinase (MAPK) signalling pathways are promising therapeutic
targets as they are commonly hyperactivated in many human cancers, including TNBC.
MAPK pathways are grouped into four cascades based on the terminal MAPKs:
extracellular signal-regulated kinase (ERK) 1/2, p38, c-Jun N-terminal kinase (JNK) and
ERK5. MAPK pathways are typically composed of three to five protein kinases: MAPK
kinase kinase (MAPKKK), MAPK kinase (MAPKK), MAPK, and MAPK-activated
protein kinases (MAPAPK). This kinase cascade transmits extracellular signals from
growth factors, ECM components, and factors released by tissue stress, including from
tumours, into intracellular signals that promote cell proliferation, survival, and
differentiation50,51.
Of the four cascades, the ERK1/2 cascade is the most frequently mutated and activated
pathway52. The ERK cascade is composed of RAS, RAF, MEK1/2, ERK1/2 and
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downstream protein kinases activated by ERK50,51. Upon activation through dual
phosphorylation at threonine and tyrosine residues by MEK1/2, ERK1/2 is translocated to
the nucleus where it phosphorylates transcription factors important for cell proliferation,
differentiation, motility, apoptosis, and angiogenesis53–55 (Figure 3). Continual activation
of the MEK/ERK cascade, usually through mutations in RAS or BRAF results in deregulated proliferation and reduced apoptosis that is conducive to tumour development52.
High levels of activated ERK1/2 occur in breast cancer tumour cells and correlate with
lymph node metastasis56,57. Furthermore, in TNBC, elevated ERK1/2 expression and
activation promotes metastasis58 and is associated with lower overall, recurrence-free, and
distant metastasis-free survival rates58–60. Inhibition of this pathway reduces tumour
progression and reverts cells to a homeostatic state in experimental models58,61,62. Because
ERK1/2 is the only substrate of MEK1/250,51,63 and has a strong role in promoting tumour
progression, targeting the MEK/ERK cascade is an enticing and potentially advantageous
approach for abrogating tumour development within TNBC.

1.6

Trametinib as a targeted therapy against the
RAS/RAF/MEK/ERK cascade in TNBC

Trametinib is a highly specific, non-ATP competitive inhibitor of MEK1/2 that inhibits
activation by RAF63. A clinical study investigating the pharmacokinetics of the
combination of dabrafenib, a BRAF inhibitor, and trametinib versus dabrafenib alone in
metastatic melanoma patients with BRAFV600E,K mutations found that the combination
therapy reduced the incidence of cutaneous squamous cell carcinoma, increased the median
progression-free survival and increased response rates64. This study and prior clinical
studies showing high response to rates to trametinib65 led to the approval of trametinib as a
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combination therapy with dabrafenib to treat unresected or metastatic melanoma patients
with B-RafV600E,K mutations66. Since then, trametinib has been investigated for its antitumour properties with several other chemotherapy agents, such as the PI3K inhibitor
BKM12067, the BCL-2 inhibitor navitoclax68, and the AKT inhibitor GSK214179569.
However, there are currently only limited clinical trials showing success with trametinib in
TNBC patients. In a single-arm multi-center study exploring the effect of trametinib or
trametinib in combination with the AKT inhibitor GSK2141795 in advanced TNBC, both
treatment options showed little efficacy in the majority of patients70. Two patients who
were administered trametinib alone experienced a partial response and one patient
administered trametinib and GSK2141795 experienced an unconfirmed partial response70.
These results highlight the heterogeneity in response to treatment within TNBC patients
and underscore the importance of identifying biomarkers that can be used to predict positive
treatment responses.
Despite some of the benefits observed with trametinib, most cancer patients experience
dose-limiting toxicities, such as rashes, diarrhea, peripheral edema and central serous
retinopathy64,65,70. Dose-limiting toxicity is a common problem with drugs that target the
MEK/ERK cascade because of its wide expression profile and involvement with multiple
homeostatic cellular processes71–73. Finding new ways to reduce these toxicities would
improve the usability of this drug. Biomarkers to tumours that are sensitive to low doses of
MEK inhibitory drugs is one approach to improving the use of this targeted therapy74,75.
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Figure 3. RAS/RAF/MEK/ERK cascade with an inhibitor of MEK. The
RAS/RAF/MEK/ERK cascade is one of four cascades in the MAPK signalling pathway.
When this pathway is activated by external stimuli, such as growth factors, RAS is
transformed into its active form through the conversion of RAS-bound GDP to GTP. This
sets off a signalling cascade where activated RAS, activates RAF, which activates MEK1/2,
which activates ERK1/2. ERK1/2 goes on to activate a diverse array of substrates that play
roles in promoting proliferation, differentiation, motility, and angiogenesis. Trametinib is
a highly specific, non-ATP competitive inhibitor of MEK1/2. Created with
Biorender.com76
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1.7

Biology of HA and RHAMM

Tumour progression and metastasis is a multi-step process that requires key contributions
from the tumour microenvironment77. Changes in the morphology and motile capability of
the primary tumours are dependent on extracellular matrix (ECM) components such as
hyaluronan (HA) and HA receptors such as the receptor for hyaluronan-mediated motility
(RHAMM), which regulate signalling through ERK1/2 to control these processes78.
HA is a glycosaminoglycan made up of repeating units of N-acetyl glucosamine and βglucuronic acid. HA is a vital ECM component implicated in regulating both anti-tumour
and pro-tumour phenotypes depending on its molecular weight. High molecular weight HA
(HMW-HA) (>500 kDa) is characterized as being anti-inflammatory and anti-fibrotic and
important for maintaining tissue architecture and hydration in homeostatic tissue79–81. In
contrast, low molecular weight HA (LMW-HA) (10-250 kDa), which is produced by
fragmentation of HMW-HA by hyaluronidases or reactive oxygen species82, is a danger
signal to promote pro-inflammatory responses, cell proliferation and migration80,81,83,84.
LMW-HA, in particular, is conducive to tumour progression in breast cancer85,86. For
example, a study exploring the prognostic potential of LMW-HA in breast cancer found
that breast cancer patients expressed higher levels of serum LMW-HA than healthy
women81,87,88. Furthermore, among breast cancer patients, higher serum LMW-HA levels
were correlated with lymph node metastases89. In addition, invasive breast cancer cell lines
produced LMW-HA to a greater extent than non-invasive cell lines89.
RHAMM (gene name HMMR) is a multifunctional HA receptor that is expressed extraand intracellularly. It is present at low concentrations in the cytoplasm of homeostatic adult
tissues81,87,88 but is highly expressed in the placenta87,88, thymus87,88, testes87,88,90, and
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spleen91,92. During tissue/cellular stress, such as during wound healing and/or
inflammation, RHAMM expression increases and is exported into the microenvironment,
where it interacts with various ECM components and growth factor receptors to facilitate
rapid tissue repair and in diseases such as cancer during tumour progression to an invasive
and metastatic state79,93,94.
Intracellular RHAMM is among a set of genes that are highly expressed during the Gap 2
(G2) and mitotic (M) phases of the cell cycle95–97, where it regulates the structure of
microtubules in each mitotic phase, controls the rate of spindle assembly and mitosis and
is important for establishing microtubule nucleation sites98,99. Localization of RHAMM to
interphase and mitotic microtubules, centrosomes and the perinucleus/nucleus predicts this
protein functions in genomic stability, proliferation, and gene transcription78,98,100,101.
Extracellular RHAMM interacts with multiple different proteins, such as platelet-derived
growth factor receptor102,103, EGFR104,105 and transforming growth factor beta
(TGFß)106,107, but its interaction with the HA receptor CD44 is required for activation of
motogenic signalling cascades such as ERK1/278,79,108,109. At the cell surface, RHAMM can
bind to LMW-HA to initiate signals that lead to increases in cell migration, tumorigenesis,
and wound repair81,84,110.

1.8

RHAMM as a prognostic factor and biomarker in
cancer

RHAMM is a marker of poor prognosis in a variety of human cancers, including breast
cancer57,111–114, multiple myeloma115,116, oral squamous cell carcinoma117, prostate
cancer118, colorectal cancer119–121, and gastric cancer122,123. Tumour cells utilize RHAMM
function to achieve metastasis because it is a key regulator of HA-mediated cell motility.

15

As such, RHAMM expression is often localized to cellular processes or the invading fronts
of tumours. In breast cancer, high RHAMM expression is observed in the focal regions of
primary tumours57, at the stromal-epithelium interface of primary breast tumours111, in the
trabeculae of budding breast tumours111, and at the nuclear envelope of experimental
BRCA1 mutant breast cancer cells124. Immunohistochemical analysis of RHAMM in breast
cancer cohorts indicates that RHAMM is increasingly present in the progression of in situ
carcinoma to invasive TNBC tumours and that distinct RHAMMhigh niches occur at the
invasive edge of aggressive TNBC tumours125. In addition, the cellular localization of
RHAMM coincides with the neoplastic potential of breast cancer subtypes. In the
aggressive MDA-MB-231 TNBC cell line, RHAMM is observed in the perinuclear regions
of cells, whereas in the less invasive MCF7 Luminal A breast cancer cell line, RHAMM is
present in the cytoplasm and on cytoskeletal structures109.

1.9

RHAMM/ERK1/2 complexes in TNBC

In TNBC, RHAMM utilizes signal transduction through the MEK/ERK cascade to promote
cell motility and proliferation57,108,109. Analyses of RHAMM and ERK1/2 expression in
breast cancer patients found that high RHAMM expression is correlated with high
expression of ERK1/2 and that these tumours are associated with a higher tumour grade57.
The expression of cell surface RHAMM is essential for the cell surface localization of
CD44108,109, and the resulting CD44-RHAMM complex is required to sense HA and for
activation as well as subcellular localization of ERK1/2 to drive high motility and invasion
in invasive breast cancer cell lines such as MDA-MB-231109 (Figure 4). Intracellular
RHAMM binds to ERK1 to act as a scaffold that complexes ERK1/2 with MEK1 to drive
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activation near substrates relevant to cell motility (e.g., cytoskeleton proteins and nuclear
transcription complexes)103,126,127 (Figure 4).
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Figure 4. RHAMM is an extracellular and intracellular protein that facilitates
MEK/ERK signal transduction. RHAMM binds to CD44 and LMW-HA at the cell
surface to promote activation of ERK1/2. Intracellular RHAMM forms complexes with
MEK1/2 and ERK1/2 to promote their activation and translocation of ERK1/2 into the
nucleus to activate motogenic and mitogenic signalling proteins.
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1.10 The evolution of cell culturing and therapy
development: From 2D to 3D cultures
Many in vitro studies exploring the effect of drug sensitivity are conducted using twodimensional (2D) cell cultures. Apart from their longstanding use in studying cell
behaviour, culturing cells in 2D is a popular method because of its ease of use, costeffectiveness, and ability to conduct high-throughput experiments. However, the results
obtained from 2D cell culture experiments are not always translated or replicated in in vivo
experiments because cells grown in 2D culture are usually flatter and more stretched than
occurs in vivo, which changes the transcriptional and translation activity of the cells128,129.
Three-dimensional (3D) cultures are a newer approach to improving in vitro to in vivo
translatability. Currently, the most common 3D models include multicellular spheroids
models, scaffold-based models, hydrogel-based models, and microfluidic chip-based
models130. While each model uses slightly different reagents and techniques, the basis
behind each is that they prevent cells from adhering to the bottom of the tissue culture plate.
This promotes more cell-to-cell vs cell-to-substratum contacts and maintains the polarity
and physical restraints present in the tumour microenvironment in vivo131–133.
Multiple cellular processes change when cells are grown in 2D and 3D cultures. Breast
cancer cells grown in 3D have been shown to form distinct spheroid morphologies,
experience reduced cell viability, exhibit increased resistance to drugs and have higher cell
metabolism134. In line with a previous study134,135, Li et al.136 found that many of the breast
cancer cell lines they tested were more resistant to doxorubicin in 3D cultures than they
were in 2D cultures. Similarly, in the same study, Li et al.136 found that the normal epithelial
cell line, MCF10A, was resistant to MEK1/2 inhibition in 3D cultures. In contrast, the
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invasive breast cancer cell line MDA-MB-231 was more sensitive to MEK1/2 inhibition in
3D cultures than in 2D cultures. Taken together, these results suggest that the response of
cells to changing environments can be complex and highly dependent on the cell type,
culture environment and stressors. Thus, studies using both 2D and 3D cell culture
techniques enable a deeper understanding of basic cellular processes and drug responses,
including how these phenotypes can be influenced by factors such as cell density, protein
interactions and changes in gene expression.
Following this logic, my thesis project used 2D and 3D cell cultures to examine the impact
of RHAMM expression on TNBC progression.

1.11 Hypothesis and Objectives
I hypothesize that RHAMM promotes TNBC proliferation through its interaction with
ERK1/2 and that RHAMM expression is a biomarker for TNBC treatment susceptibility.
The objectives of this thesis were as follows:
1. Determine the effect of RHAMM expression on proliferation and survival of MDAMB-231 tumour cells in 2D and 3D culture models
2. Determine the sensitivity of RHAMM+/+ and RHAMM-/- MDA-MB-231 TNBC cells
to chemotherapy and targeted therapy in 2D cultures
3. Elucidate the role of RHAMM expression on proliferation and drug sensitivity in
co-cultures of RHAMM+/+ and RHAMM-/- MDA-MB-231 TNBC cells in 2D cultures
I conducted my experiments using RHAMM+/+ and RHAMM-/- MDA-MB-231 cell lines
kindly gifted by Drs. J. McCarthy and A. Nelson, UMN USA. The MDA-MB-231 cell line
is characteristically known for its rapid growth, invasiveness and metastatic potential and
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is a commonly used cell line for studying TNBC137–139. Molecularly, MDA-MB-231 cell
lines have been classified as Basal B140. However, recent research shows that the cell line
more closely resembles the claudin-low subtype, which is characteristic of being ER, PR
and HER2-negative and having a high frequency of metaplastic differentiation139,141.
Additionally, the MDA-MB-231 cell line exhibits the highest HA-binding levels when
compared to other breast cancer cell lines93.

21

Chapter 2
2

Materials and Methods
2.1

Cell Culture

The human breast cancer MDA-MB-231 cell line was purchased from American Type
Culture Collection (ATCC; Manassas, USA). A RHAMM-/- MDA-MB-231 cell line was
created in the lab of Dr. James B. McCarthy (University of Minnesota, Minneapolis, MN)
using the CRISPR/CAS9 gene editing system. In brief, two guide RNAs targeting exon 3
and exon 6 of the RHAMM gene and a plasmid expressing the CAS9 enzyme with
puromycin and GFP selection constructed in the lab of Dr. Brandon Moriarity (University
of Minnesota, Minneapolis, MN) were co-transfected into the MDA-MB-231 cell line.
Clones with a RHAMM deletion were detected using genomic PCR and Western Blot
assays.
Cells were grown on 75 cm2 tissue culture flasks (Sarstedt Inc., USA) and cultured in highglucose (4.5 g/L) Dulbecco’s Modified Eagle Medium (DMEM) (Wisent BioProducts, St.
Burno, Quebec, Canada) supplemented with 10% (v/v) fetal bovine serum (Wisent
BioProducts) and 50 μg/mL Gibco™ Penicillin-Streptomycin (Invitrogen, Life
Technologies, Burlington, ON, Canada) in a 37˚C humidified atmosphere of 5% carbon
dioxide. Cells were passaged every four days at 80% confluence using 0.25%
Trypsin/EDTA 2.21mM in HBSS (Wisent Bioproducts).

2.2

Proliferation and drug sensitivity analysis

For 2D cultures, cells suspended in DMEM were seeded into 96-well plates (353072,
Corning, USA) and incubated at 37oC overnight. For 3D cell cultures, cells suspended in a

22

3:1 mixture of 4 mg/mL Corning® Matrigel® Matrix (356234, Corning, USA) and 4
mg/mL Corning™ Collagen I, High Concentration, Rat Tail (354249, Corning, USA) were
seeded into 96-well plates and incubated at 37oC for 1 hour to allow the gel to solidify.
After solidification, gels were supplemented with fresh DMEM and incubated at 37oC for
72 hours to allow spheroids to form. For proliferation experiments, fresh media was added
24- (2D cultures) and 72- hours (3D cultures) post-seeding and cells were grown for an
additional 72 hours.
Drug sensitivity experiments were conducted using doxorubicin hydrochloride (D1515,
Sigma Aldrich, USA), trametinib (GSK1120212) (S2673, SelleckChem, USA) and
paclitaxel (NSC 125973) (S1150, SelleckChem, USA). 10 mM stock solutions were created
by dissolving drugs in dimethyl sulfoxide. All dilutions were prepared from 10 mM stock
solutions using DMEM. Drugs were added 24 hours post-seeding (2D cultures) and
incubated with the cells for 72 hours. Doxorubicin was applied to triplicate wells at five
different concentrations, ranging from 0.001 μM to 10 μM in a 10-fold serial dilution.
Trametinib was applied to triplicate wells at eight different concentrations, ranging from
0.0002 μM to 76.125 μM in a 5-fold serial dilution. Paclitaxel was applied to triplicate
wells at six different concentrations, ranging from 0.0002 μM to 0.625 μM, in a 5-fold
serial dilution. Treatment wells were grown in parallel with triplicate control wells in the
same culture plate.
alamarBlue™ Cell Viability (DAL1025, ThermoFisher, USA) reagent was used in 2D
culture experiments to measure metabolic activity as a marker of survival and proliferation
as per manufacturer protocol. In brief, 10 μL of alamarBlue™ reagent was added to each
well and plates were incubated at 37oC for four hours. The reducing environment in living
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cells converts resazurin, the active ingredient in alamarBlue™, to resofurin, which is highly
fluorescent. Fluorescence was measured on a Biotek Synergy H4 Hybrid Plate Reader using
the Gen5 software at an excitation of 560 nm and an emission of 590 nm. Metabolic activity
of 3D culture experiments was quantified using the CellTiter-Glo® 3D Cell Viability
(G9681, Promega, USA) reagent as per manufacturer protocol. In brief, both the plate and
the CellTiter-Glo® reagent were equilibrated to room temperature for 30 minutes.
CellTiter-Glo® reagent was added to the media in a 1:1 mixture and cells were mixed
vigorously for 5 minutes to induce cell lysis. After the plate was allowed to settle at room
temperature for 25 minutes, the luminescence signal was on a Biotek Synergy H4 Hybrid
Plate Reader using the Gen5 software.

2.3

Analysis of RHAMM expression in breast cancer tissue

Breast cancer tissue sections with low, medium and high RHAMM-positive subset
expression

were

obtained

from

The

Human

Protein

Atlas

(https://www.proteinatlas.org/ENSG00000072571HMMR/pathology/breast+cancer#imid_853014). The DAB intensity of RHAMM staining
within each RHAMM expression subgroup was quantified using ImageJ/Fiji
(https://imagej.net/software/fiji/downloads). A Region of Interest was created by drawing
a circle around the tissue section. The Region of Interest was added to the Region of Interest
manager for subsequent analysis. The 4',6-diamidino-2-phenylindole (DAPI) channel was
separated from the DAB channel using the “Color Deconvolution” feature in Fiji. DAB
intensity of the specified Region of Interest was quantified using the “Threshold” and
“Measure” features.
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2.4

Analysis of GFP expression in Parental and RHAMM-/MDA-MB-231 co-cultures

Using 2D cultures, parental MDA-MB-231 (no GFP) and RHAMM-/- MDA-MB-231 (GFP)
cells suspended in DMEM were seeded based on the low/medium, or high RHAMM+/+
subset expression subgroups into 96-well plates and incubated at 37oC overnight. For
proliferation experiments, fresh media was added 24 hours post-seeding and cells were
grown for an additional 72 hours. Drug sensitivity experiments were conducted using
doxorubicin hydrochloride and trametinib. Twenty-four hours post-seeding, doxorubicin
and trametinib were applied to triplicate wells at five different concentrations, ranging from
0.001 μM to 10 μM in a 10-fold serial dilution and 0.0002 to 0.625 μM in a 5-fold serial
dilution, respectively, and incubated with the cells for 72 hours. Treatment wells were
grown in parallel with triplicate control wells in the same culture plate. GFP fluorescence
was measured at an excitation of 485 nm and an emission of 512 nm on a Biotek Synergy
H4 Hybrid Plate Reader using the Gen5 software.

2.5

Immunocytochemistry staining

Cells suspended in DMEM were seeded onto 12 mm coverslips (89015-725, VWR, USA)
in 24-well plates (353047, Corning, USA). 24 hours later, fresh DMEM was added to the
cells. Once cells reached 80% confluency, cells were washed with 1X tris buffered saline
(TBS) (50 mM Tris-Cl, pH 7.5, 150 mM NaCl) for 5 minutes with gentle rocking. The cells
were fixed for 10 minutes with 4% paraformaldehyde diluted in 1X TBS. After fixation,
the cells were washed twice with 1X TBS for 10 minutes each with gentle rocking. The
cells were permeabilized with 0.1% Triton-X (X100-5ML, Sigma Aldrich, USA) diluted
in 1X TBS for 10 minutes. After permeabilization, the cells were washed twice with 1X
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TBS for 10 minutes each with gentle rocking. The cells were blocked for one hour with 3%
bovine serum albumin diluted in 1X TBS. After blocking, the cells were incubated with
primary antibodies and stored in the dark, overnight at 4oC. The next day, the cells were
washed twice with 1X TBS for 10 minutes each with gentle rocking. After the wash, the
cells were incubated with secondary antibody in the dark for 1 hour (see list for antibodies
used). The cells were washed twice with 1X TBS for 10 minutes each. After the wash, two
drops of Prolong™ Gold Antifade Mountant with DAPI (P36931, Thermofisher Scientific,
USA) were added to new slides, the coverslips were removed from the wells, inverted, and
placed on top of the mountant.

2.6

Immunofluorescence staining

3D cell cultures were created by seeding cells into 24-well plates as previously described.
Spheroids were grown over a seven-day growth period. At the end of the growth period,
spheroids were fixed for paraffin processing using a protocol developed by Sarah Tarullo
(University of Minnesota, Minneapolis, MN). In brief, the media was removed after seven
days, and spheroids were fixed with 10% Neutral-Buffered Formalin for 24 hours. After
fixation, 70% ethanol was added to each well. While spheroids were covered in ethanol,
one vial of Epredia™ HistoGel™ Specimen Processing Gel (22-110-678, Fisher Scientific,
CA) was heated for 12 seconds to liquefy the gel. Once the gel was liquified, Epredia™
Disposable Base Molds (22-050-161, Fisher Scientific, CA) were placed on ice and coated
with HistoGel™. The spheroid plugs were placed on the coated moulds and additional
HistoGel™ was added to submerge the spheroid plugs. Moulds were left on ice until the
HistoGel™ solidified. Once solidified, the moulds were submerged in 10% NBF for further
paraffin processing.
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Once paraffin-embedded tissue slides were created, the slides were used for
immunofluorescence assays. Tissue sections were deparaffinized in two changes of xylene
for 15 minutes each. Xylene was removed by placing tissue sections in 100% ethanol for
10 minutes. Tissue sections were dehydrated in 95% and 70% ethanol for 10 minutes each.
Slides were rehydrated in dH2O and placed in 1X TBS buffer for 5 minutes each. Antigen
retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) and 0.1% Tween® 20
Detergent (655205, Millipore Sigma, CA) in a Panasonic microwave. Tissue sections were
washed in 1X TBS for 10 minutes with gentle rocking. After the wash, tissue sections were
blocked in 3% BSA diluted in 1X TBS for one hour with gentle rocking. Tissue sections
were incubated with primary antibodies (see list for antibodies used) and left overnight in
a tinfoil humidifier at 4oC. The next day, slides were washed in 1X TBS for 10 minutes
with gentle rocking and subsequently incubated with secondary antibodies (see list for
antibodies used) in a tinfoil humidifier for two hours at room temperature. Prolong™ Gold
Antifade Mountant with DAPI and coverslips were placed on each tissue section following
a final wash in 1X TBS for 10 minutes with gentle rocking.
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Table 1. List of primary and secondary antibodies used for immunofluorescence and
immunocytochemistry.

Primary Antibody

Catalogue Number

Dilution

9101S, Cell Signaling, USA

1:100

p44/42 MAPK (ERK1/2)

9102S, Cell Signaling, USA

1:100

Ki-67 (8D5)

9449S, Cell Signaling, USA

1:250

Secondary Antibody

Catalogue Number

Dilution

Goat anti-Mouse IgG (H+L)

A32723, ThermoFisher

Alexa Fluor™ Plus 488

Scientific, USA

Goat anti-Mouse IgG (H+L)

A32727, ThermoFisher

Phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204)

1:250

1:250
Alexa Fluor™ Plus 555

Scientific, USA

Alexa Fluor™ 555 goat anti-

A11034, ThermoFisher
1:250

rabbit IgG (H+L)

Scientific, USA

Alexa Fluor™ 555 donkey

A31572, ThermoFisher

anti-rabbit IgG (H+L)

Scientific, USA

1:250
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2.7

Image analysis of immunocytochemistry and
immunofluorescences slides

All tissue sections were imaged on an Olympus IX81 confocal microscope using the FV10ASW software at 40X magnification. Total fluorescence intensity of the antibodies of
interest was quantified using ImageJ/Fiji. The DAPI channel was separated from the other
fluorescence colours using the “Make Composite” and “Split Channels” features in Fiji.
The average size of the cells was determined using the Line tool for subsequent cell
counting using the “Threshold” and “Analyze Particles” features. Fluorescence of the
protein of interest was quantified using the “Threshold” and “Measure” features. To
specifically quantify nuclear fluorescence intensity, each analyzed particle/nuclei was
added to a manager, such that only fluorescence intensity within the recorded particles was
quantified.

2.8

Western Blot

Cells in DMEM were seeded into tissue culture dishes (353004, Corning, USA) and grown
overnight at 37oC. 24 hours later, media alone, 0.0025 μM of trametinib, 0.025 μM of
trametinib and 0.250 μM trametinib were added to each plate for an additional 72 hours.
After 72 hours, cells were washed with ice-cold 1X phosphate-buffered saline (137 mM
NaCl, 12 mM phosphate, 2.7 mM KCl, pH 7.4) and proteins were extracted from the cells
using radioimmunoprecipitation assay buffer (150 mM NaCl, 1% Nonidet P-40, 0.1%
sodium dodecyl sulphate, 0.5% sodium deoxycholate, 50 mM Tris, pH 7.4) with 1:100
Halt™ Protease & Phosphatase Inhibitor Cocktail (78440, ThermoFisher Scientific, USA).
Protein lysates were incubated in a 1:3 ratio with Laemmli Sample Buffer (1610737EDU,
Bio-Rad, USA) at 95oC for 5 minutes. After determining the protein concentration of each
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sample using the Pierce™ BCA Protein Assay Kit (23225, ThermoFisher Scientific, USA),
20 μg of protein was loaded into wells of a Bolt™ 4-12% Bis-Tris Plus gel
(NW04120BOX, ThermoFisher Scientific, USA). Protein samples were electrophoresed at
90V and transferred onto hydrophobic PVDF transfer membranes (IPVH00010, Millipore
Sigma, USA) at 30V. Membranes were blocked in 5% Milk TBST (50 mM Tris-Cl, pH
7.5, 150 mM NaCl; 0.25% Tween® 20 Detergent; 5% Skim Milk Powder) overnight at
4oC. Membranes were stained for 2 hours at room temperature with gentle rocking using
phosphorylated and total ERK1/2 primary antibodies diluted in 1% Milk TBST at 1:1000
dilutions. Membranes were washed with 1% Milk TBST twice for 10 minutes with gentle
rocking and stained with an Anti-Rabbit IgG (H+L) HRP Conjugate (W4011, Promega,
USA) for 2 hours at room temperature with gentle rocking at a 1:5000 dilution. Membranes
were submerged in 1X TBST at 4oC overnight and blocked again with 5% Milk TBST the
next day for one hour at room temperature with gentle rocking. Membranes were stained
for GAPDH (ab37168, Abcam, UK) for 2 hours at room temperature with gentle rocking
at a 1:5000 dilution. Membranes were again stained with an Anti-Rabbit IgG HRP for 2
hours at room temperature with gentle rocking at a 1:5000 dilution. Membranes were
washed with 1% Milk TBST twice for 10 minutes with gentle rocking. Membranes were
developed using Immobilon Forte Western HRP substrate (WBLUF0100, Sigma Aldrich,
USA) and imaged using the BioRad ChemiDox™ MP Imaging system.

2.9

Cyclized RHAMM peptide mimetic

The cyclized RHAMM mimetic peptide (ETI0152) was generously donated by the lab of
Dr. Len Luyt. The 14-mer cyclized peptide was derived from the alpha-helical HA-binding
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domain of the RHAMM sequence. Amino acids in domain II were ‘stapled’ together via
lactam bridges to improve bioavailability and affinity to LMW-HA.

2.10 Schedule- and Concentration-Dependent Analysis of
Synergy
Drug synergy was determined using combinations of doxorubicin, trametinib and
paclitaxel. RHAMM+/+ MDA-MB-231 cells suspended in DMEM were seeded into 96-well
plates. Drug combinations were grouped into Lower (Doxorubicin: 0.1 μM, Trametinib:
0.005 μM, Paclitaxel: 0.025 μM), Middle (Doxorubicin: 0.250 μM, Trametinib: 0.025 μM,
Paclitaxel: 0.025 μM) and Higher (Doxorubicin: 1 μM, Trametinib: 0.025 μM, Paclitaxel:
0.125 μM) based on the amount of drug added. Drug combinations were also administered
at four time schedules: Drug A 4 hours after seeding, replaced with Drug B for 68 hours,
Drug A 24 hours after seeding, replaced with Drug B for 48 hours, Drug A 48 hours after
seeding, replaced with Drug B for 24 hours, or Drug A and Drug B simultaneously 24 hours
after seeding for 72 hours, and vice versa. Cell viability was measured using the
alamarBlue™. Statistical synergy was determined using methods developed by Demidenko
and Miller, 2019142. The Bliss model of Independence was chosen to determine synergy.
The Bliss Independence model assumes that if two drugs act independently, the number of
surviving cells is the product of the independent killing events of the two drugs. The
formula for the Bliss Independence model in the presence of a control group is as follows:
𝑙𝑛𝑆𝐴 + 𝑙𝑛𝑆𝐵 − 𝑙𝑛𝑆𝐶 − 𝑙𝑛𝑆𝐴𝐵 = 0
, where SA is the fraction of living cells after treatment with Drug A, SB is the fraction of
living cells after treatment with Drug B, SC is the fraction of living cells with no drug
treatment that accounts for cells that naturally die, and SAB is the fraction of living cells
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after simultaneous treatment with Drug A and Drug B. When this equation is logtransformed, it turns into an analysis of variance (ANOVA), which can be expressed as a
linear null hypothesis.
𝐻0 : μ1 + μ2 − μ3 − μ0 = 0
. This linear null hypothesis can be tested using a test statistic T, where statistical synergy
occurs when T is positive and exceeds the critical value of the t distribution.

2.11 Statistical analyses
Experimental data are presented as mean ± standard error mean (SEM), with significance
detected at p-values < 0.05. Statistical differences between two means were assessed using
a Welch’s t-test or a Mann-Whitney test with significance set at p ≤ 0.05. Statistical
differences between three or more means were assessed using Tukey’s, Sidak’s or Dunnet’s
multiple comparison test, where significance was set at p ≤ 0.05. Statistical significance
between IC50 values of survival curves was calculated from non-linear regressions
generated in GraphPad Prism 7.04, where significance was set at p ≤ 0.05.
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Chapter 3
3

Results
3.1

RHAMM expression increases the proliferation of
MDA-MB-231 tumour cells

TNBC cells are proliferative, invasive, and often develop resistance to chemotherapy.
These characteristics enable this subtype to metastasize and form colonies in distant
locations such as the brain and the lungs17. RHAMM has been reported to be present at the
invading fronts of breast tumours and proposed to play a role in the proliferation of tumour
cells in that region through its interaction with ERK1/278,109,143. To first determine the
impact of RHAMM expression in TNBC, the proliferation of RHAMM+/+ and RHAMM-/MDA-MB-231 tumour cells was quantified in both 2D and 3D cell cultures. While 2D
cultures offer the benefits of being low-cost and easy to manage, 3D cultures are an
attractive cell culture technique as they are more representative of an in vivo
microenvironment144,145. 3D cultures allow cells to form and maintain cellular contacts due
to the matrix environment the cells are grown in131,146. This, in conjunction with various
growth factors, creates a conducive environment for spheroid formation and invasion that
more closely replicates in vivo tumour formation than in 2D cultures131,146. Additionally,
3D cultures allow for the comparison of drug response in different mechanical
environments as previous research has shown the response of cells to drug therapy can be
different between 2D and 3D cultures136,147. The RHAMM-/- MDA-MB-231 cell line was
created using CRISPR-CAS9 gene editing and achieved by transfecting cells with guide
RNAs against exons 3 and 6 of the RHAMM gene and a plasmid expressing the CAS9
enzyme. The RHAMM+/+ MDA-MB-231 cell line was created by mock-transfecting the
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cells to confirm that the transfection agents did not affect RHAMM-loss. Loss of RHAMM
protein in the RHAMM-/- MDA-MB-231 cell line was confirmed by Western Blot assays
(Figure 5A). Metabolic activity in RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells
was quantified as a measure of survival and proliferation, while Ki67 activation was
quantified as a more specific measure of proliferation in 2D and 3D cultures as it is
expressed in the active phases of the cell cycle. RHAMM+/+ MDA-MB-231 cells proliferate
more rapidly in both 2D (p=0.0282) and 3D cultures (p=0.0043) compared to RHAMM-/counterparts, as determined by alamarBlue™ and CellTiter-Glo® assays (Figure 5B, C,
D, E). RHAMM+/+ MDA-MB-231 tumour cells also express higher levels of Ki67 than
RHAMM-/- counterparts in both 2D culture (p=0.0005) and 3D spheroids (p=0.0003)
(Figure 6).

RHAMM expression is important for the activation and compartmentalization of
ERK1/2103,108. The spatial regulation of ERK1/2 by RHAMM provides cues for modulating
ERK1/2-mediated migration and invasion108. To assess whether the increase in RHAMMmediated cell proliferation is associated with the activation of ERK1/2, phosphorylated
ERK1/2 (T202/Y204) and total ERK1/2 expression were quantified in RHAMM+/+ and
RHAMM-/- MDA-MB-231 tumour cells via immunofluorescence staining. The expression
of phosphorylated ERK1/2, which is a readout of its active form, is significantly higher in
RHAMM+/+ versus RHAMM-/- 2D cells (p<0.0001) and 3D spheroids (p=0.0004), while the
expression of total ERK1/2 is not significantly modified by RHAMM-loss (Figure 7).
Taken together, these results show that RHAMM plays a role in promoting the proliferation
of MDA-MB-231 tumour cells, and this function is associated with activation of nuclear
ERK1/2.
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Changes in the microenvironment can affect multiple cellular processes, including gene
transcription, signal transduction, and the levels of cell proliferation and migration, and
these changes have been postulated to affect how cells respond to drug therapy129,133.
Therefore, I next investigated whether there are differences in proliferation and ERK1/2
activation between 2D and 3D cultures to determine the best culture method to implement
to explore the effect of RHAMM expression on drug sensitivity.
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Figure 5. RHAMM+/+ MDA-MB-231 tumour cells proliferate more rapidly than
RHAMM-/- MDA-MB-231 tumour cells. A) Western blot of RHAMM knocked out of
MDA-MB-231 tumour cells using CRISPR/Cas9 gene editing. Clone H8 was used as the
RHAMM-/- MDA-MB-231 cell line. B) RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour
cells in 2D cultures were plated at 5000 cells per well in 96-well plates and grown for 96
hours. After 96 hours, cells in 2D cultures were incubated with the alamarBlue™ reagent
for 4 hours, after which fluorescence was read at an excitation of 560 nm and an emission
of 590 nm. Fluorescence intensity was proportional to the number of viable cells as
determined by the manufacturers. Mean ± SEM, n=8, p≤0.05 (*) as determined by Welch’s
t-test. C) Representative images of 2D tumour cells at the end of the growth period taken
at 20X magnification. D) In 3D culture, cells were embedded in a 3:1 combination of
basement membrane matrix and collagen I and cells were grown for seven days. CellTiterGlo® 3D Cell Viability reagent was added, and cells were mixed vigorously for 5 minutes
before incubation with the reagent for 25 minutes, after which luminescence was recorded.
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Luminescence intensity was proportional to the number of viable cells as determined by
the manufactures. Mean ± SEM, n=6, p≤0.01 (**) as determined by the Mann-Whitney
test. E) Representative images of 3D spheroids at the end of the growth period taken at 4X
magnification.
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Figure 6. RHAMM+/+ MDA-MB-231 tumour cells express higher levels of Ki67 than
RHAMM-/- MDA-MB-231 tumour cells. A) Ki67 expression was quantified using
ImageJ/Fiji. Mean ± SEM, p≤0.001 (***) as determined by the Welch’s t-test and the
Mann-Whitney test. B) Immunofluorescence staining of Ki67 (red) in RHAMM+/+ and
RHAMM-/- MDA-MB-231 2D cells counterstained with DAPI (blue) to visualize the nuclei.
Representative images of 2D cells taken at 40X magnification. C) RHAMM+/+ and
RHAMM-/- MDA-MB-231 paraffin-embedded 3D spheroid sections stained with Ki67
(green) and counterstained with DAPI (blue) to visualize the nuclei. Representative images
of 3D spheroids taken at 40X magnification.
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Figure 7. RHAMM+/+ MDA-MB-231 tumour cells express higher levels of
phosphorylated

ERK1/2

than

RHAMM-/- MDA-MB-231 tumour cells.

A)

Phosphorylated ERK1/2 and total ERK1/2 expression were quantified using ImageJ/Fiji.
Mean ± SEM, ns = not significant, p≤0.001 (***), p≤0.0001 (****) as determined by the
Welch’s t-test and the Mann-Whitney test. B) Immunofluorescence staining of
phosphorylated ERK1/2 (green) and total ERK1/2 (green) in RHAMM+/+ and RHAMM-/MDA-MB-231 2D cells stained counterstained with DAPI (blue) to visualize the nuclei.
Representative images of 2D cells taken at 40X magnification. C) Immunofluorescence
staining of phosphorylated ERK1/2 (green) and total ERK1/2 (green) in RHAMM+/+ and
RHAMM-/- MDA-MB-231 paraffin-embedded 3D spheroid sections counterstained with
DAPI (blue) to visualize the nuclei. Representative images of 3D spheroids taken at 40X
magnification.
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3.2

The effect of RHAMM expression on Ki67 expression
and ERK1/2 activation does not differ between 2D and
3D cultures

To determine if there are culture-specific differences in proliferation and ERK1/2 activation
in RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells between 2D and 3D culture
conditions, ratios of each readout, proliferation/survival, Ki67 expression, and
phosphorylated ERK1/2, were compared. The effect of RHAMM expression on MDA-MB231 tumour cell proliferation/survival is significantly larger in 3D cultures compared to 2D
cultures (p=0.0026) (Figure 8A). In contrast, the effect of RHAMM on ERK1/2 activation
and Ki67 expression is not significantly different between 2D and 3D cultures
(phosphorylated ERK1/2: p=0.2837, total ERK1/2: p=0.0755, Ki67: p=0.4779) (Figure
8B, C). The effect of RHAMM expression on proliferation highlights important findings
on the role of RHAMM in anchorage-independent vs. dependent culture conditions, which
future work will address. Since there is no difference in the effect of RHAMM on Ki67
expression and ERK1/2 activation between 2D and 3D cell cultures, I next investigated the
role of RHAMM on drug sensitivity using 2D cultures as it facilitates assay development
and the determination of IC50.

Chemotherapy, which primarily targets proliferating cells, is the main systemic treatment
option for TNBC patients. Because RHAMM+/+ MDA-MB-231 tumour cells proliferate
more rapidly than RHAMM-/- MDA-MB-231 tumour cells, as detected by Ki67 expression,
I explored the effect of RHAMM expression on sensitivity to chemotherapy drugs that are
commonly used in TNBC to kill proliferating tumour cells.
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Figure 8. The effect of RHAMM expression between 2D and 3D cultures differs
regarding proliferation/survival, but not to Ki67 expression or ERK1/2 activation. A
ratio was created of the A) proliferation/survival, B) Ki67, C) phosphorylated ERK1/2 and
total ERK1/2 readouts between RHAMM+/+ and RHAMM-/- MDA-MB-231 cells. The
magnitude of the ratio was compared between 2D and 3D cultures. Mean ± SEM; ns = not
significant, p<0.01 (**) as determined by the Mann-Whitney test and the Welch’s t-test.
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3.3

RHAMM+/+ MDA-MB-231 tumour cells are more
sensitive to doxorubicin than RHAMM-/- MDA-MB-231
tumour cells

Doxorubicin hydrochloride (Adriamycin) is commonly used in the treatment of TNBC.
Doxorubicin induces DNA damage and apoptosis by several mechanisms, such as through
the production of free radicals148 and the inhibition of topoisomerase II activity149.
Paclitaxel, which is commonly used in combination with doxorubicin, acts as a mitotic
inhibitor through its stabilization of microtubules150. I predicted that RHAMM expression
might affect sensitivity to doxorubicin and paclitaxel because RHAMM regulates
proliferation, which doxorubicin indirectly inhibits through its induction of DNA damage
and apoptosis, and RHAMM also associates with α- and β-tubulin to regulate microtubule
dynamics, which paclitaxel abrogates98,99,126. To determine whether RHAMM expression
promotes sensitivity to doxorubicin and paclitaxel, RHAMM+/+ and RHAMM-/- MDA-MB231 tumour cells were exposed to 0.001 to 10 µM of doxorubicin or 0.001 to 100 µM of
paclitaxel for 72 hours. Cell viability was measured at the end of treatment using
alamarBlue™. Drug sensitivity was quantified by calculating the 50% inhibitory
concentration (IC50) of both doxorubicin and paclitaxel. RHAMM expression significantly
increases sensitivity of the MDA-MB-231 tumour cells to doxorubicin (RHAMM+/+ IC50:
0.1628 µM, RHAMM-/- IC50: 0.5084 µM; p=0.0002) (Figure 9A, C). In contrast, and
unexpectedly, RHAMM expression does not affect sensitivity to paclitaxel (RHAMM+/+
IC50: 0.05451 µM, RHAMM-/- IC50: 0.05727 µM; p=0.9521) (Figure 9B, D). Together,
these results suggest that RHAMM expression promotes sensitivity to doxorubicin in
TNBC tumour cells.
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RHAMM expression is often observed in heterogenous niches within tumours and the
presence of RHAMMhigh subsets is associated with tumour progression, reduced survival
in breast cancer and increased invasion93,103,113,151. To mimic this clinical context, I next
investigated the effect of varying levels of RHAMM expression on proliferation and
sensitivity to doxorubicin in co-cultures of RHAMM+/+ and RHAMM-/- MDA-MB-231
tumour cells.
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Figure 9. RHAMM expression increases sensitivity to doxorubicin, but not to
paclitaxel. A) RHAMM+/+ and RHAMM-/- MDA-MB-231 cells in 2D culture were plated at
5000 cells per well in 96-well plates and 24 hours later exposed to 0.001 to 10 µM of
doxorubicin and B) 0.002 to 100 µM of paclitaxel for an additional 72 hours. Afterwards,
cells were incubated with alamarBlue™ for 4 hours and fluorescence was read at an
excitation of 560 nm and an emission of 590 nm. Fluorescence intensity was proportional
to the number of viable cells as determined by the manufacturers. C, D) The IC50 values
were calculated from non-linear regression generated in GraphPad Prism 7.04. The
numbers above each bar represent the IC50. Mean ± SEM, n=4, ns = not significant, p≤0.001
(***).
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3.4

RHAMM expression promotes proliferation and
doxorubicin sensitivity in a heterogeneous environment
of RHAMMhigh and RHAMMlow tumour cells

RHAMM expression increases with stress such as during tissue repair and in tumour
microenvironments152,153. Within tumours, the expression of RHAMM often occurs in
heterogeneous patches57,111,125. To determine the percentage of RHAMM present in a
heterogeneous

environment,

RHAMM

expression

was

quantified

using

immunohistochemical images of breast cancer tissue sections obtained from The Human
Protein Atlas. RHAMM expression was categorized into low, medium, and high subgroups
based on analyses of RHAMM expression by two independent specialists (Figure 10A).
Breast cancer tissues with a ductal carcinoma subtype were analyzed as most TNBC
tumours fall under this category7,9. The percentage of RHAMM-positive cells within the
tissue sections was quantified from these three groups using ImageJ/Fiji. The low, medium
and high subgroups exhibited 3%, 4% and 29% RHAMM positivity, respectively (Figure
10B). Since the difference in RHAMM positivity between the low and medium subgroup
is likely based on strong, localized expression in the medium RHAMM-expressing
subgroup, the low and medium subgroups were treated as one group as it is difficult to
recapitulate that type of expression in 2D cell cultures. Thus, the low/medium and the high
groupings and the associated RHAMM positivity percentages, 4% and 29%, respectively,
were used in subsequent experiments.

To elucidate the role of RHAMM+/+ subsets on cell proliferation, co-cultures of RHAMM+/+
and RHAMM-/- MDA-MB-231 tumour cells were created. Both cell lines were seeded
together in 2D cultures in the percentages associated with the low/medium and high
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subgroups (Figure 10B). A high RHAMM+/+ MDA-MB-231 subpopulation significantly
increases cell proliferation compared to RHAMM-/- monocultures (p=0.0024) (Figure
10C). This follows a similar trend where the RHAMM+/+ MDA-MB-231 monoculture
proliferation is higher than RHAMM-/- monocultures (p=0.0458) (Figure 10C).
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Figure 10. A high RHAMM+/+ subpopulation increases cell proliferation compared to
RHAMM-/- MDA-MB-231 monocultures. A) Breast cancer tissue sections were obtained
from The Human Protein Atlas and separated into low (3% RHAMM-positivity), medium
(4% RHAMM-positivity), and high (29% RHAMM-positivity) subgroups based on their
analysis of RHAMM expression by two independent pathologists. The insets provide a
closer view of the tissue. B) The breast cancer tissue sections were analyzed for the
percentage of RHAMM expression using Image/Fiji. The numbers above each bar
represent the percentage of RHAMM+/+ subsets. Mean ± SEM. C) RHAMM+/+ and RHAMM/-

MDA-MB-231 cells were plated together in 96-well plates in 2D culture at 5000 cells per

well in the proportions determined for low/medium and high RHAMM expression and cells
were grown for 96 hours. After 96 hours, cells were incubated with the alamarBlue™
reagent for 4 hours and fluorescence was read at an excitation of 560 nm and an emission
of 590 nm. Fluorescence intensity was proportional to the number of viable cells as
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determined by the manufacturers. Mean ± SEM, n=2, p<0.05 (*), p<0.01 (**) as
determined by Tukey’s multiple comparison test.
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RHAMM+/+ tumour cells occur as subsets in the tumour microenvironment57,111,154, and
these appear to be responsible for promoting breast cancer progression125. Since RHAMM
expression promotes doxorubicin sensitivity in the MDA-MB-231 monocultures, the effect
of the presence of RHAMM+/+ cell subsets on doxorubicin sensitivity was investigated using
co-cultures to mimic the clinical situation. To begin to assess if RHAMM-positivity can be
a biomarker for sensitivity and to determine if doxorubicin can efficiently kill RHAMM+/+,
but not RHAMM-/-, tumour cells, RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells
were seeded in the same proportions associated with the low/medium and high subgroups
(Figure 11A) and treated with varying amounts of doxorubicin. RHAMM+/+, low/medium
RHAMM+/+ subsets, high RHAMM+/+ subsets and RHAMM-/- MDA-MB-231 tumour cells
were exposed to 0.001 to 10 µM of doxorubicin for 72 hours. Cell viability was quantified
at the end of treatment by measuring proliferation/survival via alamarBlue™ and
determining the IC50. Both the low/medium and high RHAMM+/+ subsets of MDA-MB-231
tumour cells in co-cultures with RHAMM-/- tumour cells increase sensitivity to doxorubicin
(Low/Medium IC50: 0.2639 µM vs. RHAMM-/- IC50: 0.5084 µM, p=0.0342; High IC50 =
0.2074 µM vs. RHAMM-/- IC50: 0.5084 µM, p=0.0022) compared to RHAMM-/monocultures (Figure 11B, C). Taken together, these results demonstrate that RHAMM is
a potential biomarker for doxorubicin sensitivity and that the presence of RHAMM+/+ cell
subsets can increase sensitivity to doxorubicin.

Since doxorubicin kills proliferating cells due to its inhibition of DNA replication, I next
assessed whether doxorubicin is specifically targeting the RHAMM+/+ MDA-MB-231
tumour cells in the heterogenous environment because they proliferate more rapidly than
RHAMM-/- tumour cells.
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Figure 11. A low/medium and high RHAMM+/+ subpopulation increases sensitivity to
doxorubicin compared to monocultures of RHAMM-/- MDA-MB-231 tumour cells. A)
Co-cultures were separated based on RHAMM expression into low/medium and high. The
numbers above each bar represent the percentage of RHAMM+/+ subsets. Mean ± SEM. B)
RHAMM+/+ and RHAMM-/- MDA-MB-231 cells were plated together in 96-well plates in
2D culture at 5000 cells per well in the proportions determined for low/medium and high
RHAMM expression and 24 hours later treated with 0.001 to 10 µM of doxorubicin for an
additional 72 hours. Afterwards, cells were incubated with alamarBlue™ for 4 hours and
fluorescence was read at an excitation of 560 nm and an emission of 590 nm. Fluorescence
intensity was proportional to the number of viable cells as determined by the manufacturers.
C) The IC50 values were calculated from non-linear regression generated in GraphPad
Prism 7.04. The numbers above each bar represent the IC50. Mean ± SEM, n=2, p≤0.05 (*),
p≤0.01 (**), p≤0.001 (***)
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3.5

Doxorubicin specifically targets RHAMM+/+ MDA-MB231 subsets in a heterogeneous environment

To create the RHAMM-/- MDA-MB-231 cell line, guide RNAs targeting RHAMM and a
plasmid expressing the CAS9 enzyme with puromycin and GFP selection were cotransfected into the MDA-MB-231 cells. This allowed GFP expression to be measured to
estimate the quantity of the RHAMM-/- MDA-MB-231 tumour cells in the heterogeneous
population. A parental MDA-MB-231 cell line, which expresses RHAMM, but not GFP,
was used as a RHAMM+/+ MDA-MB-231 cell line. Low/medium RHAMM-expressing cocultures of the parental MDA-MB-231 and RHAMM-/- MDA-MB-231 tumour cells were
treated with 0.001 to 100 µM of doxorubicin for 72 hours in 2D cultures. GFP expression
was measured before drug treatment and 72 hours after drug treatment to determine the
percent change in GFP expression. Even though cell viability is decreasing in a
concentration-dependent manner, the percent change in GFP expression upon doxorubicin
treatment is not significantly different from control (Figure 12A). In fact, as the
concentration of doxorubicin increases, the ratio between GFP expression, which is an
indicator of the RHAMM-/- tumour cells, and cell viability increases (Figure 12B). These
results suggest that the RHAMM-/- tumour cells dominate in treated cultures, and the
RHAMM+/+ tumour cells are increasingly killed by doxorubicin.

RHAMM+/+ cell subsets are implicated in promoting breast cancer progression through the
regulation of proliferation and motility57,113. As such, doxorubicin-mediated apoptosis of
RHAMM+/+ cell subsets has important clinical applications for the management of TNBC.
Furthermore, these findings also highlight the potential use of RHAMM as a biomarker to
identify aggressive tumour cell subsets.
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RHAMM has previously been shown to regulate activation and subcellular localization of
the MEK/ERK pathway, specifically through its ability to form MEK/ERK1/2 complexes
and regulate ERK1/2 translocation79,109. Since ERK1/2 is the only substrate of
MEK1/250,51,63, I hypothesized that inhibition of this pathway, by targeting MEK1/2, would
preferentially affect the survival of RHAMM+/+ MDA-MB-231 tumour cells. Trametinib is
a reversible and potent MEK1/2 inhibitor that is currently used to treat unresectable or
metastatic melanoma155,156. ERK1/2 inhibition affects multiple cellular processes, such as
proliferation, survival, differentiation, immune responses, and senescence157. Hence,
trametinib is an ideal drug to investigate whether the RHAMM signalling pathway can be
exploited to detect and/or increase drug sensitivity. I next verified the association between
RHAMM expression and phosphorylated ERK1/2 in the MDA-MB-231 tumour cells by
quantifying phosphorylated and total ERK1/2 protein levels via Western Blot, as an
assessment of whether RHAMM expression predicts effective targeting of ERK1/2.
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Figure 12. Doxorubicin specifically targets RHAMM+/+ subsets in heterogenous cocultures. A) RHAMM+/+ and RHAMM-/- MDA-MB-231 cells were plated together in 96well plates in 2D culture at 5000 cells per well in the proportions determined for
low/medium RHAMM expression and 24 hours later treated with 0.001 to 10 µM of
doxorubicin. Only the RHAMM-/- MDA-MB-231 cells are transfected with GFP, allowing
for the distinction of RHAMM-/- MDA-MB-231 cells from RHAMM+/+ subsets. GFP
fluorescence was measured at an excitation of 485 nm and an emission of 512 nm before
adding doxorubicin and 72 hours after. Mean ± SEM, n=3, upper-case letters that are the
same are not significantly different from one another, lower-case letters that are the same
are not significantly different from one another, d: p≤0.001 (***), e: p≤0.0001 (****) as
determined by Tukey’s multiple comparison test. B) The ratio between GFP expression and
cell viability at each concentration of doxorubicin tested.
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3.6

RHAMM+/+ MDA-MB-231 tumour cells express higher
levels of phosphorylated ERK1/2 protein

RHAMM and ERK1/2 have experimentally been shown to directly interact to promote the
transcription of key cell motility genes and regulate cytoskeletal structures126,153. To assess
the effect of RHAMM expression on ERK activity, phosphorylated ERK1/2 (T202/Y204)
and total ERK1/2 were quantified in RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour
cells using Western Blot assays. The amount of phosphorylated ERK1/2 protein is
significantly higher in the RHAMM+/+ MDA-MB-231 tumour cells compared to the
RHAMM-/- tumour cells (p=0.0102), while the amount of total ERK1/2 protein is not
different (Figure 13). Since RHAMM+/+ MDA-MB-231 tumour cells exhibited increased
ERK1/2 activation, I next investigated whether the interaction between RHAMM and
ERK1/2 can be targeted for treatment by the MEK1/2 inhibitor trametinib.
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Figure 13. RHAMM+/+ MDA-MB-231 tumour cells express higher levels of
phosphorylated ERK1/2 protein than RHAMM-/- MDA-MB-231 tumour cells. A)
RHAMM+/+ and RHAMM-/- MDA-MB-231 cells were seeded into 2D culture plates and
grown for 96 hours, after which, proteins were isolated from the cells and stained for
phosphorylated ERK1/2 and total ERK1/2. B) Protein levels were quantified using ImageJ
and normalized to GAPDH. Mean ± SEM, ns = not significant, p≤0.05 (*) as determined
by Sidak’s multiple comparison test.
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3.7

RHAMM+/+ MDA-MB-231 tumour cells are more
sensitive to trametinib than RHAMM-/- comparators

To determine if there are RHAMM-dependent alterations in trametinib sensitivity,
RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells were exposed to 0.0002 to 78.125
µM of trametinib for 72 hours. Cell viability and IC50 were measured at the end of
treatment. RHAMM expression significantly increases the sensitivity of MDA-MB-231
tumour cells to trametinib (RHAMM+/+ IC50: 0.0172 µM, RHAMM-/- IC50: 0.9618 µM;
p≤0.0001) (Figure 14). Only a small number of clinical trials have shown success in using
trametinib to treat TNBC. In the published clinical trials, few TNBC patients reached the
primary endpoints of the studies since they experienced dose-limiting toxicities70,158.
Together, these findings suggest that RHAMM may be a useful biomarker to identify
patients whose tumours would respond to lower, tolerated doses of this targeted therapy.

To verify that trametinib inhibits the activation of ERK1/2 at the IC50, RHAMM+/+ MDAMB-231 cells were treated with 0.0025, 0.025 and 0.250 µM of trametinib for 72 hours.
0.0025, 0.025 and 0.25 µM of trametinib were chosen because they fall before, near and
after the IC50 for RHAMM+/+ MDA-MB-231 tumour cells treated with the drug.
Phosphorylated and total ERK1/2 protein levels in RHAMM+/+ MDA-MB-231 tumour cells
after 72 hours of drug treatment were visualized and quantified using Western Blot assays.
RHAMM+/+ MDA-MB-231 tumour cells exposed to 0.250 µM of trametinib express
significantly lower phosphorylated ERK1/2 protein compared to control (p=0.0165), while
the levels of total ERK1/2 remain unchanged (Figure 15).
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Cell-surface RHAMM is important for promoting HA/RHAMM/CD44/ERK1/2 complexes
at the cell surface that regulate ERK1/2 signalling108,109. Therefore, I next used a cyclized
RHAMM peptide mimetic developed by Drs. Luyt and Turley159 to determine if the
RHAMM-mediated increase in trametinib sensitivity requires RHAMM/HA interactions.
The cyclized RHAMM peptide mimics the HA-binding region of RHAMM and binds to
LMW-HA. Therefore, it is expected to block cell surface RHAMM/HA signalling, which
is a requirement for activation of the MEK/ERK cascade through RHAMM109.
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Figure 14. RHAMM+/+ MDA-MB-231 cells are more sensitive to trametinib than
RHAMM-/- MDA-MB-231tumour cells. A) RHAMM+/+ and RHAMM-/- MDA-MB-231
cells in 2D culture were plated at 5000 cells per well in 96-well plates and 24 hours later
exposed to 0.0002 to 78.125 µM of trametinib for an additional 72 hours. Afterwards, cells
were incubated with alamarBlue™ for 4 hours and fluorescence was read at an excitation
of 560 nm and an emission of 590 nm. Fluorescence intensity was proportional to the
number of viable cells as determined by the manufacturers. B) The IC50 values were
calculated from non-linear regression generated in GraphPad Prism 7.04. The numbers
above each bar represent the IC50. Mean ± SEM, n=3, p≤0.0001 (****).
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Figure 15. RHAMM+/+ MDA-MB-231 tumour cells express lower phosphorylated
ERK1/2 protein in response to trametinib. A) RHAMM+/+ MDA-MB-231 cells were
seeded into 2D culture plates and 24 hours later treated with 0.0025, 0.025 and 0.250 µM
of trametinib for 72 hours. After 72 hours, proteins were isolated from the cells and stained
for phosphorylated ERK1/2 and total ERK1/2. B) Protein levels were quantified using
ImageJ and normalized to GAPDH. Mean ± SEM, upper-case letters that are the same are
not significantly different from one another, lower-case letters that are the same are not
significantly different from one another, B: p≤0.05 (*), as determined by Dunnett’s multiple
comparison test.
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3.8

Sensitivity to trametinib is facilitated through cell
surface RHAMM/HA interactions

To elucidate whether the increase in trametinib sensitivity is facilitated through interactions
with HA at the cell surface, the sensitivity of the RHAMM+/+ MDA-MB-231 tumour cells
to trametinib in the presence of a cyclized peptide that blocks RHAMM/HA interactions at
the cell surface was assessed. RHAMM+/+ MDA-MB-231 tumour cells were exposed to a
combination of 0.0025, 0.025 and 0.25 µM of trametinib and 1, 10 and 20 µM of the
cyclized peptide for 72 hours. Cell viability was measured at the end of this treatment.
While exposure of RHAMM+/+ MDA-MB-231 tumour cells to 0.0025 µM of trametinib
significantly decreases cell viability compared to control (p=0.0021), the addition of 1, 10
or 20 µM of the cyclized peptide with 0.0025 µM of trametinib increases cell viability such
that it is not significantly different compared to control (Figure 16A, B, C). Furthermore,
the addition of 1 µM of the cyclized peptide with 0.0025 µM of trametinib significantly
increases cell viability compared to 0.0025 µM of trametinib alone (Figure 16A). The
cyclized peptide thus induces a response to trametinib that is similar to RHAMM-/- MDAMB-231 tumour cells. Together, the results suggest that trametinib sensitivity is facilitated
through cell surface RHAMM/HA interactions.

Because the RHAMM+/+ MDA-MB-231 monocultures are highly sensitive to targeted
therapy via trametinib compared to the RHAMM-/- MDA-MB-231 monocultures, I next
employed co-cultures of RHAMM+/+ and RHAMM-/- MDA-MB-231 to determine whether
the RHAMM+/+ cell subsets can promote sensitivity to trametinib in a more clinically
relevant model.
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Figure 16. Trametinib sensitivity in RHAMM+/+ MDA-MB-231 tumour cells may be
facilitated through cell surface RHAMM/HA interactions. RHAMM+/+ MDA-MB-231
cells were plated at 5000 cells per well in 96-well plates and 24 hours later treated with A)
1, B) 10, and C) 20 µM of cyclized peptide alone, 0.0025 µM of trametinib alone or
combinations of cyclized peptide and trametinib for 72 hours. After 72 hours, cells were
incubated with the alamarBlue™ reagent for 4 hours, after which fluorescence was read at
an excitation of 560 nm and an emission of 590 nm. Mean ± SEM, n=2, ns = not significant,
p≤0.01 (**) as determined by Tukey’s multiple comparisons test.
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3.9

RHAMM expression promotes trametinib sensitivity in
co-cultures of RHAMM+/+ and RHAMM-/- MDA-MB231 tumour cells

To assess if RHAMM+/+ subsets generate trametinib sensitivity in RHAMM-/- cultures,
RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells were seeded in the proportions
associated with the low/medium (4% RHAMM positivity) and high (29% RHAMM
positivity) subgroups (Figure 17A) and treated with 0.0002 to 0.625 µM of trametinib for
72 hours. Cell viability was measured at the end of treatment and drug sensitivity was
assessed by determining the IC50. The low/medium and high RHAMM+/+ subsets of MDAMB-231 tumour cells in co-cultures with RHAMM-/- tumour cells increase sensitivity to
trametinib (Low/Medium IC50: 0.1579 µM vs. RHAMM-/- IC50: 0.9618 µM, p=0.0130; High
IC50 = 0.07125 µM vs. RHAMM-/- IC50: 0.9618 µM, p=0.0004) compared to RHAMM-/monocultures (Figure 17B, C). The sensitivity of both subgroups to trametinib is
significantly less than the RHAMM+/+ monocultures (RHAMM+/+ IC50: 0.0172 µM vs
Low/Medium IC50: 0.1579 µM, p<0.0001; RHAMM+/+ IC50: 0.0172 µM vs High IC50:
0.07125 µM, p<0.0004) (Figure 17B, C). Because the co-cultures do not promote an IC50
as low as the pure cultures of RHAMM+/+ MDA-MB-231 tumour cells, the results indicate
that the effect of trametinib is highly dependent on the levels of RHAMM expression,
where high RHAMM expression is predictive of high trametinib sensitivity. Taken
together, these results suggest that the presence of RHAMM+/+ subsets can promote
sensitivity to trametinib. This has potential clinical significance as it provides a rationale
for using RHAMM as a biomarker for trametinib sensitivity.
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To elucidate whether RHAMM can be therapeutically targeted in TNBC, I next used cocultures of RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells, that more closely
approximate clinical tumours, to investigate whether trametinib can specifically induce
apoptosis of the RHAMM+/+ subsets.
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Figure 17. A low/medium and high RHAMM+/+ subpopulation increases sensitivity to
trametinib compared to monocultures of RHAMM-/- tumour cells. A) Co-cultures were
separated based on RHAMM expression into low/medium and high. The numbers above
each bar represent the percentage of RHAMM+/+ subsets. Mean ± SEM. B) RHAMM+/+ and
RHAMM-/- MDA-MB-231 cells were plated together in 96-well plates in 2D culture at 5000
cells per well in the proportions determined for low/medium and high RHAMM expression
and 24 hours later treated with 0.0002 to 3.125 µM of trametinib for an additional 72 hours.
Afterwards, cells were incubated with alamarBlue™ for 4 hours and fluorescence was read
at an excitation of 560 nm and an emission of 590 nm. Fluorescence intensity was
proportional to the number of viable cells as determined by the manufacturers. C) The IC50
values were calculated from non-linear regression generated in GraphPad Prism 7.04. The
numbers above each bar represent the IC50. Mean ± SEM, n=2, p≤0.05 (*), p≤0.001 (***),
p≤0.0001 (****).
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3.10 Trametinib specifically targets RHAMM+/+ MDA-MB231 subsets in co-cultures
To explore the potential clinical significance of RHAMM as a therapeutic target,
low/medium RHAMM-expressing co-cultures made up of parental (GFP-negative) and
RHAMM-/- (GFP-positive) MDA-MB-231 tumour cells were treated with 0.0002 to 0.625
µM of trametinib for 72 hours. GFP expression was quantified 24 hours after seeding and
after 72 hours of exposure to trametinib to determine the percent change in GFP expression
caused by trametinib. Cell viability significantly decreases at high concentrations of
trametinib, but the percent change in GFP expression does not change compared to control
(Figure 18A). Unlike with doxorubicin where the ratio between GFP expression and cell
viability increased as the concentration of doxorubicin increased, the ratio between GFP
expression and cell viability in response to trametinib is the highest between 0.0002 and
0.025 µM, meaning that the RHAMM-/- MDA-MB-231 tumour cells die at higher
concentrations of trametinib (Figure 18B). These results suggest that the dose-limiting
toxicities observed with trametinib may be due to apoptosis of homeostatic tissue, which
does not seem to occur with doxorubicin. Collectively, these results suggest that RHAMM
is a biomarker of trametinib sensitivity in TNBC cells and that trametinib can induce
apoptosis of the RHAMM+/+ subsets at lower, tolerated doses, which has clinical utility.

The use of biomarkers in TNBC may enhance treatment efficacy in the absence of known
targetable receptors due to the ability of biomarkers to highlight susceptible tumour
populations. Combination therapies combining chemotherapy drugs with drugs that target
aberrant pathways are often administered to reduce drug resistance and improve drug
efficacy compared to monotherapies74,160. However, the clinical advancement of these
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combination therapies has been hindered by a lack of predictive markers of sensitivity,
including in TNBC12,52. Therefore, I next explored whether the presence of RHAMM in the
MDA-MB-231 tumour cells can indicate sensitivity to a combination of chemotherapy,
using doxorubicin or paclitaxel, and targeted therapy, using trametinib.
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Figure 18. RHAMM+/+ subsets are specifically targeted by low concentrations of
trametinib in heterogenous co-cultures. A) RHAMM+/+ and RHAMM-/- MDA-MB-231
cells were plated together in 96-well plates in 2D culture at 5000 cells per well in the
proportions determined for low/medium RHAMM expression and 24 hours later treated
with 0.0002 to 0.625 µM of trametinib. Only the RHAMM-/- MDA-MB-231 cells are
transfected with GFP, allowing for the distinction of RHAMM-/- MDA-MB-231 cells from
RHAMM+/+ subsets. GFP fluorescence was measured at an excitation of 485 nm and an
emission of 512 nm before adding doxorubicin and 72 hours after. Mean ± SEM, n=3,
upper-case letters that are the same are not significantly different from one another, lowercase letters that are the same are not significantly different from one another, b: p≤0.05
(***) as determined by Tukey’s multiple comparisons test. B) The ratio between GFP
expression and cell viability at each concentration of trametinib tested.
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3.11 The combination of doxorubicin and trametinib act
independently in RHAMM+/+ MDA-MB-231 cells
depending on the concentration and schedule
The effect of a drug combination can be categorized as being synergistic, independent, or
antagonistic. Synergism occurs when two drugs together produce an effect, such as cell
death, greater than either drug alone. Independence occurs when two drugs work
independently and produce an effect equal to either drug alone. Antagonism occurs when
two drugs together produce an effect that is worse than either drug alone.

To determine if RHAMM expression can promote synergy between doxorubicin, which
targets rapidly dividing cells, and trametinib, which targets the MEK/ERK pathway and
multiple cell functions, RHAMM+/+ MDA-MB-231 tumour cells were exposed to various
combinations of doxorubicin and trametinib in a concentration- and time-dependent
manner then cell viability was measured at the end of the treatment. As previously
determined, the IC50 of RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells treated with
doxorubicin and trametinib is 0.1628 and 0.5084 µM and 0.0172 and 0.9618 µM,
respectively. Therefore, 0.1, 0.250 and 1 µM of doxorubicin and 0.005 and 0.025 µM of
trametinib were chosen as they are near the recorded IC50s. Drug pairs were categorized
into three groups, LOWER ([Doxorubicin] = 0.1 µM, [Trametinib] = 0.005 µM), MIDDLE
([Doxorubicin] = 0.250 µM, [Trametinib] = 0.025 µM) and HIGHER ([Doxorubicin] = 1
µM, [Trametinib] = 0.025 µM) based on the strengths of the concentrations. In addition,
the drug pair was administered on a sequential- or simultaneous-based schedule that was
composed of either treatment with Drug A for 4, 24 or 48 hours, followed by replacement
with Drug B for 68, 48 or 24 hours, respectively, and vice versa. Simultaneous drug
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administration is limited by the possibility that one drug may inhibit the function of the
other. Sequential treatments provide the opportunity for each drug to function to its full
capacity before its removal. Out of the 21 possible combinations of doxorubicin and
trametinib, 9 act independently, and 12 act antagonistically (Table 2). Half of the
antagonist combinations occur with doxorubicin at 0.250 µM and trametinib at 0.025 µM,
regardless of the administration schedule (Table 2). Taken together, these results indicate
that while not every combination was antagonistic, there was no synergy present between
doxorubicin and trametinib in the RHAMM+/+ MDA-MB-231 tumour cells. Therefore, I
next investigated the synergistic potential of paclitaxel and trametinib since RHAMM
regulates microtubule dynamics and RHAMM expression was a strong indicator of
trametinib sensitivity.

69

Table 2. The combination of doxorubicin and trametinib in RHAMM+/+ MDA-MB231 tumour cells is antagonistic or independent depending on the schedule and
concentration.

Doxorubicin and Trametinib

DOXa

TRAb

Time

for

for

DOX

TRA

Fold
Label

Conc.

Time

p-value

Interpretation

Synergy

Conc.

0.1

0.005

LOWER

4

68

1.318

0.0357

Independentd

0.1

0.005

LOWER

24

48

1.242

0.1427

Antagonisticc

0.1

0.005

LOWER

48

24

1.014

0.9111

Independent

0.1

0.005

LOWER

68

4

0.889

0.4255

Antagonistic

0.1

0.005

LOWER

48

24

0.704

0.0205

Antagonistic

0.1

0.005

LOWER

24

48

0.966

0.8462

Independent

0.1

0.005

LOWER

0.732

0.1725

Antagonistic

0.25

0.025

MIDDLE

4

68

0.96

0.8661

Antagonistic

0.25

0.025

MIDDLE

24

48

0.669

0.0976

Antagonistic

0.25

0.025

MIDDLE

48

24

0.555

0.0120

Antagonistic

72
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a

MIDDLE

68

4

0.668

0.0660

Antagonistic

0.25

0.025

MIDDLE

48

24

0.619

0.0663

Antagonistic

0.25

0.025

MIDDLE

24

48

0.834

0.6096

Independent

0.25

0.025

MIDDLE

0.727

0.2768

Antagonistic

1

0.025

HIGHER

4

68

1.205

0.3709

Antagonistic

1

0.025

HIGHER

24

48

0.755

0.1856

Independent

1

0.025

HIGHER

48

24

0.608

0.0256

Independent

1

0.025

HIGHER

68

4

0.634

0.0399

Independent

1

0.025

HIGHER

48

24

0.669

0.0785

Antagonistic

1

0.025

HIGHER

24

48

1.161

0.5703

Independent

1

0.025

HIGHER

0.86

0.5601

Independent

72

72

TRA = Trametinib

Antagonism = two drugs in combination produce effects worse than each drug alone

d

e

0.025

DOX = Doxorubicin

b

c

0.25

Independent = two drugs in combination produce effects similar to each drug alone

Synergism = two drugs in combination produce effects greater than each drug alone
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3.12 The combination of 0.025 µM paclitaxel for 4 hours,
replaced by 0.005 µM trametinib for 68 hours is
synergistic in RHAMM+/+ MDA-MB-231 cells
Paclitaxel induced a similar level of apoptosis in the RHAMM+/+ and RHAMM-/- MDA-MB231 tumour cells, indicating that the MDA-MB-231 tumour cells are sensitive to paclitaxel
and its effect on microtubule stability, but this does not depend upon RHAMM expression.
To determine if RHAMM expression can promote synergy between paclitaxel, which
stabilizes microtubules, and trametinib, which reduced survival of RHAMM+/+ MDA-MB231 tumour cells, RHAMM+/+ MDA-MB-231 tumour cells were treated with various
combinations of paclitaxel and trametinib and cell viability was measured at the end of the
treatment. Drug pairs were categorized into three groups, LOWER ([Paclitaxel] = 0.025
µM, [Trametinib] = 0.005 µM), MIDDLE ([Paclitaxel] = 0.025 µM, [Trametinib] = 0.025
µM) and HIGHER ([Paclitaxel] = 0.125 µM, [Trametinib] = 0.025 µM). Out of the 21
possible combinations, 16 are independent, 4 are antagonistic and 1 is synergistic (Table
3). Synergism occurs at the lower concentration range when the MDA-MB-231 tumour
cells are treated with 0.025 µM of paclitaxel for four hours, replaced by 0.005 µM of
trametinib for 68 hours (p=0.0357), which is a concentration of trametinib that specifically
killed RHAMM+/+ tumour cells (Table 3). Since both drugs target cellular structures and
proteins that interact with RHAMM to promote proliferation, these results highlight the
ability of the RHAMM signalling pathway to be specifically targeted for enhanced
sensitivity to therapy.
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Table 3. Synergy in RHAMM+/+ MDA-MB-231 tumour cells treated with paclitaxel
and trametinib is schedule- and concentration-dependent.

Paclitaxel and Trametinib

PACa

TRAb

Time

for

for

PAC

TRA

Fold
Label

Conc.

Time

p-value

Interpretation

Synergy

Conc.

0.025

0.005

LOWER

4

68

1.318

0.0357

Synergistice

0.025

0.005

LOWER

24

48

1.242

0.1427

Independentd

0.025

0.005

LOWER

48

24

1.014

0.9111

Independent

0.025

0.005

LOWER

68

4

0.889

0.4255

Independent

0.025

0.005

LOWER

48

24

0.704

0.0205

Antagonisticc

0.025

0.005

LOWER

24

48

0.966

0.8462

Independent

0.025

0.005

LOWER

0.732

0.1725

Independent

0.025

0.025

MIDDLE

4

68

0.96

0.8661

Independent

0.025

0.025

MIDDLE

24

48

0.669

0.0976

Independent

0.025

0.025

MIDDLE

48

24

0.555

0.0120

Antagonistic

0.025

0.025

MIDDLE

68

4

0.668

0.0660

Independent

72

73

a

MIDDLE

48

24

0.619

0.0663

Independent

0.025

0.025

MIDDLE

24

48

0.834

0.6096

Independent

0.025

0.025

MIDDLE

0.727

0.2768

Independent

0.125

0.025

HIGHER

4

68

1.205

0.3709

Independent

0.125

0.025

HIGHER

24

48

0.755

0.1856

Independent

0.125

0.025

HIGHER

48

24

0.608

0.0256

Antagonistic

0.125

0.025

HIGHER

68

4

0.634

0.0399

Antagonistic

0.125

0.025

HIGHER

48

24

0.669

0.0785

Independent

0.125

0.025

HIGHER

24

48

1.161

0.5703

Independent

0.125

0.025

HIGHER

0.86

0.5601

Independent

72

72

TRA = Trametinib

Antagonism = two drugs in combination produce effects worse than each drug alone

d

e

0.025

PAC = Paclitaxel

b

c

0.025

Independent = two drugs in combination produce effects similar to each drug alone

Synergism = two drugs in combination produce effects greater than each drug alone
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Chapter 4
4

Discussion

Identifying and developing targeted treatments for TNBC remains an ongoing challenge as
TNBC patients lack ER, PR and HER2 expression required for current endocrine
therapies7,8,11. Traditional chemotherapy without biomarker guides remains the main
therapeutic approach for this subgroup of patients7,12,161. Thus, the discovery of novel
biomarkers and therapeutic targets is required to improve patient outcomes.

4.1

RHAMM regulates the proliferation of MDA-MB-231
tumour cells and nuclear trafficking of ERK1/2

To begin to assess whether RHAMM regulates TNBC progression, I investigated the effect
of RHAMM expression on cell proliferation/survival and ERK1/2 activation. Cell
proliferation is dependent on the ability of cells to initiate and progress through an
exquisitely controlled cell cycle162. The cell cycle is separated into four distinct phases,
Gap 0 (G0)/Gap 1 (G1), Synthesis (S), G2, and M, that are tightly regulated to ensure proper
cell division162. RHAMM is highly expressed in the G2/M phase of the cell cycle97,99,163
and regulated and balanced expression of RHAMM is important for proper cell cycle
progression164. For example, inhibition of RHAMM causes an accumulation of cells stalled
in G2 and the metaphase portion of the mitotic cycle99,165. Moreover, interfering with
RHAMM/HA interactions suppresses the synthesis of Cdc2 and Cyclin B1, which are
required for entry into mitosis165. In my study, RHAMM expression promoted proliferation
of MDA-MB-231 tumour cells in both 2D and 3D cultures, which corresponds with prior
research in this lab showing that RHAMM expression promotes the proliferation of MDAMB-231 tumour cells in 2D culture166. Moreover, Ki67 was expressed to a higher extent in
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the RHAMM+/+ MDA-MB-231 tumour cells when compared to the RHAMM-/- MDA-MB231 tumour cells in both 2D and 3D cultures, predicting that RHAMM promotes cell
proliferation through its ability to facilitate progression through the cell cycle as Ki67 is
present during the active phases of the cell cycle, including the G1, S, G2 and M phases167.
Dynamic instability is important for facilitating cell division in the cell cycle as cells rely
on the constant growth and shrinkage of microtubules to accurately segregate their
DNA168,169. ERK1/2 kinases have been linked to mechanisms by which RHAMM regulates
microtubule stability. For example, Tolg et al.126 found that RHAMM binds directly and
indirectly to MEK1 and ERK1/2, allowing them to bind to tubulin and phosphorylate
microtubule-associated proteins that regulate dynamic instability. In addition to regulating
microtubule dynamics, RHAMM has been shown to promote cell proliferation through its
interaction with ERK1/2. Zhang et al.103 demonstrated that intracellular RHAMM binds to
ERK1 and acts as a scaffold protein, forming a complex with ERK2 and MEK1. This
complex promotes phosphorylation and dimerization of ERK1/2, which is required for
translocation into the nucleus103,170. In the human cementifying fibroma cell line,
overexpression of RHAMM facilitates phosphorylation and activation of ERK1/2 in nuclei,
which promotes the proliferation of the osteoblastic cells105,171. In my study, RHAMM+/+
MDA-MB-231 tumour cells displayed higher levels of nuclear phosphorylated ERK1/2
than RHAMM-/- MDA-MB-231 tumour cells in both 2D and 3D cultures, which predicts
that RHAMM expression increases cell proliferation of TNBC tumour cells by promoting
the activation and translocation of ERK1/2 into the nucleus, where it can phosphorylate
substrates important for cell survival and proliferation172,173. Collectively, these results
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support my hypothesis that RHAMM interacts with ERK1/2 to promote cell proliferation,
through the regulation of cell cycle progression and microtubule dynamics.
RHAMM is well characterized for its role in promoting cell motility109,174–177. In fact,
RHAMM was first identified based on its ability to regulate HRAS-mediated cellular
migration174. Studies have implicated RHAMM in promoting proliferation in various cell
backgrounds, such as in lung cancer178, smooth muscle179, and leukemic cells180. However,
few studies have investigated the role RHAMM specifically plays in promoting breast
cancer proliferation and how environmental changes affect the response of RHAMM. In
my study, the presence of RHAMM imparted a significantly greater effect on TNBC
proliferation/survival in a 3D environment. These results suggest that the proteome
regulated by RHAMM depends on the context of the environment, such as whether the
cells are in a stiff fibrotic environment as observed in 2D cultures or suspended in cell
clusters as observed in 3D cultures. In line with this idea, Veiseh et al.93 demonstrated that
suspended 10T½ cells rely on RHAMM as its primary HA receptor, whereas adherent
10T½ cells do not. Therefore, the presence of RHAMM in a 3D environment that suspends
tumour cells in a matrix and stimulates cell-to-cell contact has a profound effect on the
proliferation/survival of MDA-MB-231 tumour cells, possibly due to differences in the use
of RHAMM to bind HA. Further studies using flow cytometry to determine whether there
are differences in the levels of RHAMM between MDA-MB-231 tumour cells grown in
2D culture versus 3D culture will provide valuable insight into the mechanism through
which RHAMM promotes TNBC proliferation/survival in 3D cultures.
The effect of RHAMM expression on Ki67 expression and ERK1/2 activation in TNBC
tumour cells was not different between a 2D and 3D cell culture environment, suggesting
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that the effect of RHAMM expression on basic tumour survival phenotypes, such as cell
cycle progression and activation of the MAPK pathway, through the activation and
translocation of ERK1/2, is independent of a 2D vs. 3D microenvironment. This, along
with previous research demonstrating that the MDA-MB-231 tumour cells respond to
chemotherapeutic drugs, such as paclitaxel and doxorubicin similarly between 2D and 3D
cultures129, provided the rationale for using 2D cultures to elucidate the effect of RHAMM
expression on drug sensitivity in TNBC.

4.2

RHAMM is a biomarker of doxorubicin sensitivity and
a therapeutic target for doxorubicin in MDA-MB-231
tumour cells

RHAMM directly interacts with α- and β-tubulins and regulates interphase and mitotic
spindle microtubules126. Overexpression or inhibition of RHAMM negatively impacts
microtubule dynamics99,126. Therefore, I hypothesized that knockout of its expression
would affect sensitivity or response to paclitaxel, which is a common chemotherapeutic
used to treat TNBC that functions by promoting microtubule stability through the assembly
and stabilization of tubulin dimers181. This increased microtubule stability is detrimental to
cells, as it prevents the natural reorganization of microtubules required for interphase and
mitotic spindle functioning181. In contrast to my hypothesis, RHAMM expression did not
confer increased sensitivity to paclitaxel, meaning that both the RHAMM+/+ and RHAMM-/MDA-MB-231 tumour cells were sensitive to the drug. An in vitro study using colon cancer
cells demonstrated that paclitaxel promoted a p53-mediated downregulation of RHAMM
mRNA expression levels163. This raises the possibility that paclitaxel may be promoting
the downregulation of RHAMM via p53 such that the RHAMM+/+ MDA-MB-231 tumour
cells display a RHAMM-/- phenotype, which would abrogate any differences in sensitivity
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based on RHAMM expression. Additional research is required to understand the
involvement of p53 and the interplay between microtubule stability by paclitaxel and
microtubule instability by RHAMM. Taken together, these results suggest that MDA-MB231 tumour cells are sensitive to paclitaxel, but RHAMM expression does not increase
sensitivity.
Doxorubicin is a commonly used chemotherapy agent for both neoadjuvant and adjuvant
chemotherapy in TNBC patients. Doxorubicin promotes apoptosis by intercalating with
DNA to prevent DNA synthesis, generating reactive oxygen species that damage DNA,
and blocking topoisomerase II to reduce transcription148,149,182. Failed efforts to repair the
DNA damage induced by doxorubicin ultimately lead to apoptosis. Unfortunately, many
TNBC patients develop resistance to doxorubicin, which negatively affects treatment
efficacy and reduces their overall survival183–186. Despite the development of resistance
observed in many patients, a subset of TNBC patients respond well to chemotherapy and
have better overall survival rates compared with all breast cancer subtypes14. This stresses
the importance of discovering biomarkers within the tumour cells and their
microenvironments that can indicate susceptibility to treatment. In my study, RHAMM+/+
MDA-MB-231 tumour cells were more sensitive to doxorubicin than RHAMM-/- MDAMB-231 tumour cells. These results confirm prior work in this lab, showing that RHAMM/-

cells are resistant to doxorubicin166 and underscore the importance of RHAMM

expression in promoting doxorubicin sensitivity in TNBC tumour cells. The effect of
RHAMM on doxorubicin sensitivity has been explored in other cancer backgrounds such
as colon and liver cancer. For example, in colon HCT116 tumour cells and liver HepG2
tumour cells that express p53, doxorubicin treatment reduces the levels of RHAMM mRNA
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and promotes cell cycle arrest in G1 and G2163. However, limited work has specifically
explored the role of RHAMM on doxorubicin sensitivity in breast cancer, including TNBC.
My results suggest that RHAMM expression induces sensitivity to doxorubicin in the
TNBC MDA-MB-231 cell line possibly due to its ability to promote cell proliferation,
which increases the probability of generating doxorubicin-mediated DNA breaks and
initiating apoptosis187–189. Taken together, these results predict that RHAMM expression
provides an indicator of sensitivity to doxorubicin in TNBC and supports my hypothesis
that RHAMM expression increases cell sensitivity to therapy.

4.3

Small niches of RHAMM-expressing tumour cells can
increase cell proliferation and sensitivity to
chemotherapy

RHAMM is commonly found in heterogenous niches throughout tumours, most often at
the outer edge and invasive fronts57,111. Here, I found that human breast cancer tissue from
The Human Protein Atlas denoted as expressing low, medium, and high levels of RHAMM
contained an average of approximately 3%, 4% and 29% RHAMM-positive tumour cells,
respectively. This is consistent with prior research showing that RHAMM expression can
vary between 0 and 50% depending on the levels of tumour differentiation 88,190. I further
showed that only a high RHAMM+/+ subpopulation increased cell proliferation in cocultures of RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells compared to a
completely RHAMM-/- monoculture. Further experiments staining the RHAMM-/- MDAMB-231 tumour cells with an anti-GFP antibody will provide insight into the cell type
composition of RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells at the end of the
growth period. These results support a previous study implicating high RHAMMexpressing subsets in promoting breast cancer progression125. For example, a 27-gene
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RHAMM-dependent signature (RDS), composed of genes associated with the cell cycle,
the epithelial-to-mesenchymal pathway, and the mitotic spindle, was identified, where high
expression of this gene signature was correlated with lymph node metastasis and a high
tumour grade. Furthermore, immunohistochemical and digital spatial transcript profiling
demonstrated that RDS gene expression was the highest at the invasive front of tumours,
predicting that RDS expression in these focal regions is responsible for activating
RHAMM-mediated processes important for invasion and metastasis125. The increase in
proliferation also raises the possibility that in a heterogeneous environment the RHAMM+/+
MDA-MB-231 tumour cells could be undergoing paracrine signalling directly or indirectly
that promotes the proliferation of the surrounding RHAMM-/- tumour cells. However,
further research is required to understand the specific mechanisms in play. Nevertheless,
these results highlight important findings on the ability of small subsets of RHAMM to
promote TNBC proliferation.
Using the heterogeneous co-cultures, I also showed that both a low/medium and high
RHAMM+/+ subpopulation increased the sensitivity of MDA-MB-231 tumour cells to
doxorubicin compared to a completely RHAMM-/- environment. Analysis of GFP
expression, which was only present in the RHAMM-/- tumour population, demonstrated that
the increase in doxorubicin sensitivity was likely attributed to the ability of doxorubicin to
specifically target and kill the proliferative RHAMM+/+ MDA-MB-231 tumour cells, as the
levels of RHAMM-/- MDA-MB-231 tumour cells did not significantly change compared to
control as the concentration of doxorubicin increased. To my knowledge, this is the first
study to investigate the effect of subsets of tumour cells with varying levels of RHAMM
on doxorubicin sensitivity in TNBC.
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Taken together, these results suggest that subsets of MDA-MB-231 tumour cells with high
RHAMM expression promote tumour proliferation even in an environment of RHAMM-/tumours. Importantly, the ability to specifically target a proliferative and invasive tumour
population, such as the RHAMM+/+ tumour cells, has major clinical implications for TNBC
treatment because it can improve drug efficiency and reduce the incidences of off-target
apoptosis and toxicity.

4.4

RHAMM increases sensitivity to targeting the
MEK/ERK signalling cascade

Western Blot analysis showed that RHAMM+/+ MDA-MB-231 tumour cells expressed
higher levels of phosphorylated ERK1/2 protein than RHAMM-/- MDA-MB-231 tumour
cells. These results are consistent with studies showing that RHAMM promotes ERK1/2
activation in breast cancer57,109,191 and that MDA-MB-231 cells express high levels of
phosphorylated ERK1/2192,193. Many clinical studies have been conducted to investigate the
efficacy of various MEK and ERK inhibitors52. However, a lack of predictive biomarkers
has hindered the successful deployment of these inhibitors in the clinical setting 52.
RHAMM has been shown to interact and form a complex with MEK1/ERK1/2, which
affects the subcellular compartmentalization and activation of ERK1/2103,108,126. There are
numerous therapeutic benefits of targeting the RHAMM/MEK1/ERK1/2 complex because
of the conditional expression of RHAMM and limited binding interactions within RHAMM
and MEK1. For example, RHAMM expression is upregulated in response to tissue stress,
such as those induced by a tumour microenvironment81. HA is the ligand of RHAMM, so
targeting RHAMM/HA interactions would reduce RHAMM signalling79,81. Furthermore,
MEK1/2 are the only upstream activators of ERK1/2, so targeting MEK1/2 would inhibit
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downstream activation of the MEK/ERK signalling pathway170,194. Although the MAPK
signalling pathway is important for various basic cellular processes, such as differentiation,
motility, and angiogenesis195, the connection between RHAMM and activation of the
MEK/ERK cascade is important for tumorigenesis105,109,171. This makes RHAMM
expression an indicator of MEK/ERK signalling and a potentially useful biomarker for
targeting sensitivity in TNBC. Therefore, I hypothesized that inhibition of the MEK/ERK
signalling pathway in RHAMM+/+ MDA-MB-231 tumour cells by the MEK1/2 inhibitor
trametinib would reduce TNBC tumour progression. Leung et al.193 found that MDA-MB231 cells are the most sensitive to trametinib compared to other breast cancer cell lines,
such as MCF-7 and T47D. Consistent with this study and supportive of my hypothesis,
RHAMM+/+ MDA-MB-231 tumour cells were significantly more sensitive to trametinib
than RHAMM-/- MDA-MB-231 tumour cells. Additionally, the effect of RHAMM
expression on drug sensitivity was much stronger in response to trametinib than to
doxorubicin. This raises the possibility that trametinib can be used as a novel standard-ofcare treatment option for TNBC patients with high RHAMM expression. The possibility of
administering trametinib as a standard treatment option has already been demonstrated in
ovarian cancer patients. In a phase II/III clinical trial, Gershenson et al.196 found that
patients who received trametinib had a higher median progression-free survival than
patients who received a standard-of-care treatment drug (i.e., paclitaxel, doxorubicin,
topotecan, letrozole or tamoxifen). Furthermore, patients treated with trametinib
experienced an overall response rate four times higher than patients treated with the
standard-of-care treatment. Future work using in vivo models will help to determine
whether the effect of RHAMM expression on trametinib sensitivity is translatable to the
clinical setting.
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Increased sensitivity to MEK1/2 inhibition based on RHAMM expression was further
solidified in heterogenous co-cultures of RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour
cells. Both low/medium and high RHAMM subpopulations increased sensitivity to
trametinib compared to a 100% RHAMM-/- environment. This effect was likely due to the
selective targeting and killing of the RHAMM+/+ tumour cells by trametinib as GFP
expression, which was a readout of RHAMM-/- MDA-MB-231 tumour cells, did not
significantly change compared to control as the concentration of trametinib increased. The
RHAMM+/+ MDA-MB-231 monocultures treated with trametinib had a significantly lower
IC50 than both the low/medium and high co-cultures, possibly due to variations in the
number of RHAMM-expressing tumour cells and the level of RHAMM signalling. For
instance, while investigating the connection between HA content and RHAMM and CD44
expression, Carvalho et al.197 found that only 5% of MDA-MB-231 cells were RHAMMpositive. Therefore, the difference in sensitivity to trametinib between the RHAMM+/+
MDA-MB-231 monocultures and the low/medium and high co-cultures in my study may
result from the co-cultures expressing lower levels of RHAMM in the tumour cells, which
could reduce the number of tumour cells that are susceptible to trametinib. Importantly,
these results suggest that trametinib sensitivity may be linearly related to the quantity of
RHAMM+/+ subsets in the tumour microenvironment, which could provide a clinically
relevant algorithm to predict trametinib sensitivity. Future experiments using co-cultures
of RHAMM-expressing parental MDA-MB-231 tumour cells that do not express GFP with
GFP-expressing RHAMM-/- MDA-MB-231 tumour cells to distinguish the two cell types or
flow-cytometry to detect RHAMM in the tumour cells via a RHAMM antibody will provide
insight on the percentage of RHAMM present in each subpopulation and shed light on
whether differences in RHAMM expression affect the magnitude of RHAMM signalling
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and sensitivity to trametinib. Together, these results demonstrate that RHAMM expression
promotes sensitivity to trametinib in the MDA-MB-231 tumour cells and that the RHAMM
signalling pathway could be targeted, specifically through RHAMM/ERK1/2 interactions,
to improve drug sensitivity in TNBC.
To identify the mechanisms by which RHAMM induces high trametinib sensitivity, I
investigated whether there were changes in ERK1/2 activation in response to trametinib
and whether sensitivity was mediated by cell surface RHAMM/HA interactions. In my
study, I found that trametinib decreased the protein levels of phosphorylated ERK1/2 in the
RHAMM+/+ MDA-MB-231 tumour cells. This is consistent with multiple studies showing
that trametinib decreases phosphorylated ERK1/2 expression in vitro193,198,199. Additional
experiments exploring the effect of trametinib on phosphorylated ERK1/2 expression in the
RHAMM-/- MDA-MB-231 tumour cells are required to understand whether the mechanism
of inhibition is facilitated by blocking the activity of ERK1/2 or by modifying subcellular
localization.
RHAMM plays a central role in mediating changes in HA content in the
microenvironment197, and interactions between HA, and the HA receptors, CD44 and
RHAMM, promote activation of ERK1/2108, including in MDA-MB-231 tumour cells109.
Here, I determined that trametinib sensitivity may be mediated by cell surface
RHAMM/HA interactions. In my study, blocking cell surface RHAMM/HA interaction
with a cyclized peptide that mimics the HA binding region of RHAMM rescued the
viability of RHAMM+/+ MDA-MB-231 tumour cells treated with a low concentration of
trametinib, suggesting that interactions between cell surface RHAMM and HA are required
to facilitate trametinib-mediated apoptosis. Future experiments examining ERK1/2
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activation in peptide-treated MDA-MB-231 tumour cells should be conducted to determine
whether blockage of cell surface RHAMM/HA interactions affects ERK1/2 expression.
A biomarker, such as RHAMM, that can identify treatment-sensitive tumours is an asset in
overcoming chemoresistance and dose-limiting toxicities, which are primary limitations to
the success of clinical TNBC treatments200. Taken together, these results support the
hypothesis that RHAMM expression increases sensitivity to therapy, specifically with
trametinib, and highlight novel avenues through which RHAMM expression can be used
for targeted treatment against TNBC.

4.5

RHAMM promotes synergy between paclitaxel and
trametinib in a schedule- and concentration-dependent
manner

Monotherapies aimed at targeting specific hyper-activated pathways or mutated genes have
shown better responses in clinical trials compared to generalized treatment201,202. However,
tumours are well characterized for their genomic instabilities, and these instabilities often
lead to genetic alterations that provide novel resistance to treatments that were once
effective203. Combination therapies that target multiple genes simultaneously help to
overcome this limitation, as they prevent aberrant pathways from working in tandem to
increase resistance. Determining the most effective drug combinations is a challenge due
to the vast number of combinations possible. Additionally, effectiveness can also depend
on the schedule and concentrations at which the drugs are administered204. For instance,
Vogus et al.205 found that sequentially exposing MDA-MB-231 cells to gemcitabine
followed by doxorubicin inhibited more cell growth than exposure to doxorubicin followed
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by gemcitabine or simultaneous exposure and significantly increased caspase activity
compared to single-agent exposure to doxorubicin.
To understand the mechanisms that mediate doxorubicin resistance in breast cancer,
Christowitz et al.206 explored the involvement of signalling pathways, such as the
MAPK/ERK and PI3K/Akt pathways, as they have been shown to protect cells from
apoptosis through the regulation of cell proliferation, metabolism and gene transcription207–
209

. Between the MAPK/ERK and PI3K/Akt pathways, doxorubicin resistance in breast

tumours was found to be associated with increases in phosphorylated ERK1/2 expression,
whereas there were no significant changes in the expression of PI3K/Akt markers206; thus
providing the rationale for inhibiting the MAPK/ERK pathway to improve doxorubicin
efficacy. In this study, the combination of doxorubicin and trametinib was hypothesized to
synergistically promote apoptosis of the RHAMM+/+ MDA-MB-231 tumour cells, since
RHAMM has been implicated in promoting the proliferation of these tumour cells, likely
through its interaction with the MEK/ERK cascade. Furthermore, RHAMM expression
increased the sensitivity of the RHAMM+/+ MDA-MB-231 tumour cells to both doxorubicin
and trametinib. Surprisingly, the combination of doxorubicin and trametinib either
simultaneously or sequentially in the RHAMM+/+ MDA-MB-231 tumour cells did not
provide synergistic effects. Prior research has shown that trametinib can antagonize the Pglycoprotein-mediated efflux of doxorubicin to increase the anti-tumour effect of
doxorubicin210,211. In my study, the concentration of doxorubicin administered was between
20 to 40 times higher than trametinib because the MDA-MB-231 cells were more resistant
to doxorubicin. Thus, at the concentrations tested, there may not have been enough
trametinib present to prevent P-glycoprotein, for example, from binding to and expelling
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doxorubicin from the cells. Further research investigating the synergistic effect of
doxorubicin at much lower concentrations can address this theory.
Apart from its role in proliferation, RHAMM is known to interact with microtubules and
regulate their dynamics. RHAMM co-localizes with the mitotic spindles of dividing cells
and along the entire length of microtubules in interphase cells98–100. Although RHAMM
expression did not increase paclitaxel sensitivity, the MDA-MB-231 tumour cells were still
sensitive to paclitaxel. Since both paclitaxel and RHAMM have strong connections to
microtubules, I hypothesized that paclitaxel may enhance the RHAMM-dependent effect
of trametinib. In my study, the sequential administration of paclitaxel followed by
trametinib was synergistic in the RHAMM+/+ MDA-MB-231 tumour cells, meaning that the
drugs worked together to promote cell death more than either drug alone. Multiple
preclinical and clinical studies have shown that the combination of paclitaxel and
trametinib is a promising combination treatment. For example, a pilot study found that daily
administration of paclitaxel and trametinib resulted in either a partial response or a stable
disease in eight out of twelve anaplastic thyroid cancer patients, with only two patients
discontinuing treatment due to toxicity212. In a preclinical model of pancreatic ductal
adenocarcinoma, the combination of trametinib with paclitaxel had a trend towards an
additive effect on tumour reduction and significantly increased the median survival
compared to the control213. In this study, the time of administration and the concentrations
used were major determinants of synergy. I hypothesized that the addition of paclitaxel
before trametinib allows paclitaxel to induce mitotic arrest and prevent RHAMM from
promoting cell cycle progression, making it easier for trametinib to induce apoptosis
through its inhibition of the MEK/ERK cascade. In line with this idea, I hypothesized that
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since RHAMM+/+ MDA-MB-231 tumour cells are highly sensitive to trametinib, the
addition of trametinib before paclitaxel prevents paclitaxel from imparting any synergistic
effect because most of the cells are likely already dead. An analysis of the cell cycle
distribution of lung cancer cells after treatment with paclitaxel found that paclitaxel can
induce p53-dependent G1-like arrest after multiple cell cycles, so long as the concentration
of paclitaxel is low214. Trametinib has been shown to arrest cells in the G1 phase215–217.
Thus, in this study, the addition of a low concentration of paclitaxel could have arrested the
MDA-MB-231 tumour cells in G1, providing an ideal environment for trametinib.
Additional research exploring the cell cycle distribution of the MDA-MB-231 tumour cells
after combination treatment with paclitaxel and trametinib will provide a further
understanding of how these drugs work in tandem to induce apoptosis. The tumour
environment is a complex system that relies on interactions between multiple cell pathways
to evade apoptosis and survive. Taken together, my results suggest that targeting the
pathways and interactions responsible for RHAMM-mediated proliferation and survival,
through paclitaxel and trametinib, can prove beneficial for TNBC treatment.

4.6

Limitations and Future Directions

This study provided insight into the importance of RHAMM on drug sensitivity in TNBC.
While these results were beneficial in expanding our understanding of RHAMM function,
additional research is required to elucidate the specific mechanisms that promote RHAMMmediated proliferation and drug sensitivity. For example, differentially staining the
RHAMM+/+ and RHAMM-/- MDA-MB-231 tumour cells in the heterogenous co-cultures
will allow us to determine whether the RHAMM+/+ cells are promoting proliferation of the
surrounding RHAMM-/- cells through paracrine signalling or whether the RHAMM+/+ cells
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are proliferating so rapidly they form a larger niche than originally observed.
Immunofluorescence staining and western blot assays of Ki67 and Cleaved Caspase-3 will
provide further confirmation of cell death upon doxorubicin and trametinib treatment in
RHAMM+/+ breast cancer cells. Both RHAMM and the drugs administered in this study
have been shown to affect cell cycle progression. For example, RHAMM silencing has
been shown to impact mitotic progression164. MDA-MB-231 tumour cells treated with
trametinib and doxorubicin are arrested in the G1215,216 and G2/M205,218 phases of the cell
cycle, respectively. Thus, cell cycle analyses will help determine the cell cycle distribution
of cells upon loss of RHAMM expression or drug administration. Knowing where TNBC
cells are in the cell cycle may inform which cell cycle proteins are upregulated or
downregulated. This knowledge may lead to developments in targeted combination therapy
that can promote and/or take advantage of arrested cells.
One of the limitations of this study was that all the experiments were conducted using the
invasive MDA-MB-231 TNBC cell line. Breast cancer cell lines vary in their level of
invasiveness and tumorigenicity. This can affect which signalling pathways are utilized and
how the cells respond to stimuli. For instance, Hamilton et al.109 found that the more
invasive MDA-MB-231 cell line expressed higher levels of HA, CD44, RHAMM, and
ERK1/2 than the less invasive MCF7 cell line. Furthermore, co-localization of RHAMM,
CD44 and ERK1/2 only occurred in the MDA-MB-231 cell line, and this interaction is
important for the motile capabilities of the cells. Thus, future studies exploring the effect
of RHAMM expression on proliferation and drug sensitivity in other TNCB cell lines or
less invasive cell lines, such as the MCF7 cell line, will aid in determining whether the
effect of RHAMM is linked to the invasiveness of the breast cancer cells.

90

Using 2D cultures in this study allowed for the initial determination of the effect of
RHAMM expression on drug sensitivity in the TNBC tumour cells. However, the response
of tumour cells to various stimuli depends on the context of their environment. For
example, Vogus et al.205 found that treating MDA-MB-231 cells with gemcitabine followed
by doxorubicin in vitro was the most synergistic administration schedule. However, in vivo,
the order in which the drugs were administered made no difference in tumour inhibition205.
Using patient-derived tumours, Cromwell et al.219 found that the IC50 for paclitaxel was
~100 times higher than the IC50s for trametinib and romidepsin and higher than the recorded
IC50s for paclitaxel in 2D culture. Future studies using 3D cultures and in vivo mouse
models will address the limitations of 2D cultures. This will be important in determining
whether the effect of RHAMM expression on drug sensitivity is translatable to the human
environment.

4.7

Significance and Conclusions

The novel findings presented in this study suggest that RHAMM is a biomarker and
therapeutic target in TNBC. RHAMM promotes the proliferation and survival of TNBC
tumour cells and induces sensitivity to the conventional breast cancer chemotherapy drug
doxorubicin and a novel targeted breast cancer therapy drug trametinib. In breast cancer,
RHAMM is observed in heterogeneous niches at the peripheral edge of tumours125. The
interaction of RHAMM and HA within these niches activates RHAMM signalling that
promotes invasive growth and metastasis125. Importantly, this study suggests that these
proliferative and invasive RHAMM+/+ niches can be targeted for apoptosis by doxorubicin
and trametinib, which has vast implications for the clinical treatment of TNBC.
Furthermore, this study suggests that various facets of the RHAMM signalling pathway,
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such as its interaction with microtubules and the MEK/ERK cascade, can be targeted
through combination therapy to promote increased drug sensitivity and apoptosis.
Developing effective targeted treatments for TNBC is important as most TNBC patients
develop resistance to standard-of-care chemotherapy treatments and, as such, experience
poor overall survival outcomes. TNBC is a highly heterogeneous and complex disease.
Biomarkers that aid in identifying proliferative tumour populations can inform on the
underlying biology of the tumour, which helps immensely in promoting successful
treatment response and providing a personalized cancer treatment strategy.
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